HJB1HaroldBursteinHarold John Burstein, M.D., Ph.D.42.33789600000000-71.1072493000000051067Burstein, HaroldJohn617/632-2624Professor of Medicinecatalyst:advisorInMentoringCompletedStudentProjectcompleted student projectscatalyst:eCommonsLogineCommons LoginMentoring - Completed Student Projectprns:coAuthorOfcoauthor ofprns:endDateend dateFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:physicalNeighborOfphysical neighborprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:principalInvestigatorNameprincipal investigator nameprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:startDatestart dateprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:address2address line 2vivo:address3address line 3vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionGrantvivo:hasResearchArearesearch areasvivo:hasResearcherRoleresearch activitiesvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:middleNamemiddle name or initialvivo:overviewoverviewvivo:personInPositionpositionsvivo:phoneNumberphonePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titleResearcher Rolevivo:researcherRoleOfresearcher role ofvivo:roleContributesTocontributes tovivo:sponsorAwardIdsponsor award idrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonAuthorship 100888111498829Burstein HJ, Bunnell CA, Winer EPSeminars in oncologyNew cytotoxic agents and schedules for advanced breast cancer. Semin Oncol. 2001 Aug; 28(4):344-58.Semin Oncol2001-08-01T00:00:002001New cytotoxic agents and schedules for advanced breast cancer.10572612Burstein HJ, Ramirez MJ, Petros WP, Clarke KD, Warmuth MA, Marcom PK, Matulonis UA, Parker LM, Harris LN, Winer EPAnnals of oncology : official journal of the European Society for Medical OncologyPhase I study of Doxil and vinorelbine in metastatic breast cancer. Ann Oncol. 1999 Sep; 10(9):1113-6.Ann Oncol1999-09-01T00:00:001999Phase I study of Doxil and vinorelbine in metastatic breast cancer.11027744Burstein HJ, Winer EPThe New England journal of medicinePrimary care for survivors of breast cancer. N Engl J Med. 2000 Oct 12; 343(15):1086-94.N Engl J Med2000-10-12T00:00:002000Primary care for survivors of breast cancer.Authorship 1052388529523670Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Lyons J, Marcom PK, Mayer IA, McCormick B, Moran MS, O'Regan RM, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Sitapati A, Smith KL, Smith ML, Soliman H, Somlo G, Telli ML, Ward JH, Kumar R, Shead DAJournal of the National Comprehensive Cancer Network : JNCCNBreast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018 Mar; 16(3):310-320.J Natl Compr Canc Netw2018-03-01T00:00:002018Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology.Authorship 101854116111459Burstein HJExpert review of anticancer therapyHighlights of the American Society of Clinical Oncology annual meeting 2005. 13-17 May, 2005, Florida, USA. Expert Rev Anticancer Ther. 2005 Aug; 5(4):581-3.Expert Rev Anticancer Ther2005-08-01T00:00:002005Highlights of the American Society of Clinical Oncology annual meeting 2005. 13-17 May, 2005, Florida, USA.3753910Dohnal JC, Bowie LJ, Burstein HJClinical chemistryDegree of unsaturation of the fatty acid chains of phospholipids influences the fluorescence polarization: implications for evaluating fetal lung maturity. Clin Chem. 1986 Mar; 32(3):425-8.Clin Chem1986-03-01T00:00:001986Degree of unsaturation of the fatty acid chains of phospholipids influences the fluorescence polarization: implications for evaluating fetal lung maturity.Authorship 104891317139244Sledge GW, Rugo HS, Burstein HJClinical advances in hematology & oncology : H&OThe role of angiogenesis inhibition in the treatment of breast cancer. Clin Adv Hematol Oncol. 2006 Oct; 4(10 Suppl 21):1-10; quiz 11-2.Clin Adv Hematol Oncol2006-10-01T00:00:002006The role of angiogenesis inhibition in the treatment of breast cancer.17512430Burstein HJSeminars in oncologyBiological basis of breast cancer: an introduction. Semin Oncol. 2007 Apr; 34(2 Suppl 3):S1-3.Semin Oncol2007-04-01T00:00:002007Biological basis of breast cancer: an introduction.18323544Mayer EL, Burstein HJJournal of clinical oncology : official journal of the American Society of Clinical OncologyWeighing a dose-dense option for adjuvant chemotherapy and trastuzumab in early-stage breast cancer. J Clin Oncol. 2008 Mar 10; 26(8):1198-200.J Clin Oncol2008-03-10T00:00:002008Weighing a dose-dense option for adjuvant chemotherapy and trastuzumab in early-stage breast cancer.18939346Burstein HJJournal of the National Comprehensive Cancer Network : JNCCNOncology teamwork. J Natl Compr Canc Netw. 2008 Sep; 6(8):715.J Natl Compr Canc Netw2008-09-01T00:00:002008Oncology teamwork.19930972Burstein HJJournal of the National Comprehensive Cancer Network : JNCCNScreening contretemps: the real issue in the mammogram guideline debate. J Natl Compr Canc Netw. 2009 Nov; 7(10):1039-40.J Natl Compr Canc Netw2009-11-01T00:00:002009Screening contretemps: the real issue in the mammogram guideline debate.20495080Burstein HJJournal of the National Comprehensive Cancer Network : JNCCNRe-engineering the cooperative groups. J Natl Compr Canc Netw. 2010 May; 8(5):505.J Natl Compr Canc Netw2010-05-01T00:00:002010Re-engineering the cooperative groups.Authorship 1058030229633098Exman P, Burstein HJAnnals of surgical oncologyHow Old is Too Old? Breast Cancer Treatment in Octogenarians. Ann Surg Oncol. 2018 06; 25(6):1458-1460.Ann Surg Oncol2018-04-09T00:00:002018How Old is Too Old? Breast Cancer Treatment in Octogenarians.15738533Burstein HJ, Winer EPJournal of clinical oncology : official journal of the American Society of Clinical OncologyHER2 or not HER2: that is the question. J Clin Oncol. 2005 Jun 01; 23(16):3656-9.J Clin Oncol2005-02-28T00:00:002005HER2 or not HER2: that is the question.19755043Allred DC, Carlson RW, Berry DA, Burstein HJ, Edge SB, Goldstein LJ, Gown A, Hammond ME, Iglehart JD, Moench S, Pierce LJ, Ravdin P, Schnitt SJ, Wolff ACJournal of the National Comprehensive Cancer Network : JNCCNNCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry. J Natl Compr Canc Netw. 2009 Sep; 7 Suppl 6:S1-S21; quiz S22-3.J Natl Compr Canc Netw2009-09-01T00:00:002009NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry.23486448Burstein HJJournal of the National Comprehensive Cancer Network : JNCCNKeeping cancer patients out of the hospital at the end of life. J Natl Compr Canc Netw. 2013 Mar 01; 11(3):229-30.J Natl Compr Canc Netw2013-03-01T00:00:002013Keeping cancer patients out of the hospital at the end of life.Authorship 1064166229733336Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B, André F, Baselga J, Bergh J, Bonnefoi H, Brucker SY, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Khaled H, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu BAnnals of oncology : official journal of the European Society for Medical OncologyDe-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2018 Oct 01; 29(10):2153.Ann Oncol2018-10-01T00:00:002018De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.18283035Burstein HJ, Storniolo AM, Franco S, Forster J, Stein S, Rubin S, Salazar VM, Blackwell KLAnnals of oncology : official journal of the European Society for Medical OncologyA phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol. 2008 Jun; 19(6):1068-74.Ann Oncol2008-02-17T00:00:002008A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer.19652071Abel GA, Burstein HJ, Hevelone ND, Weeks JCJournal of clinical oncology : official journal of the American Society of Clinical OncologyCancer-related direct-to-consumer advertising: awareness, perceptions, and reported impact among patients undergoing active cancer treatment. J Clin Oncol. 2009 Sep 01; 27(25):4182-7.J Clin Oncol2009-08-03T00:00:002009Cancer-related direct-to-consumer advertising: awareness, perceptions, and reported impact among patients undergoing active cancer treatment.12846423Burstein HJ, Demetri GD, Mueller E, Sarraf P, Spiegelman BM, Winer EPBreast cancer research and treatmentUse of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Res Treat. 2003 Jun; 79(3):391-7.Breast Cancer Res Treat2003-06-01T00:00:002003Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study.21713372Dominici L, Najita J, Hughes M, Niland J, Marcom P, Wong YN, Carter B, Javid S, Edge S, Burstein H, Golshan MBreast cancer research and treatmentSurgery of the primary tumor does not improve survival in stage IV breast cancer. Breast Cancer Res Treat. 2011 Sep; 129(2):459-65.Breast Cancer Res Treat2011-06-29T00:00:002011Surgery of the primary tumor does not improve survival in stage IV breast cancer.14551340Burstein HJThe New England journal of medicineBeyond tamoxifen--extending endocrine treatment for early-stage breast cancer. N Engl J Med. 2003 Nov 06; 349(19):1857-9.N Engl J Med2003-10-09T00:00:002003Beyond tamoxifen--extending endocrine treatment for early-stage breast cancer.Authorship 10716001029863451Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Láng I, Gómez HL, Tondini C, Ciruelos E, Burstein HJ, Bonnefoi HR, Bellet M, Martino S, Geyer CE, Goetz MP, Stearns V, Pinotti G, Puglisi F, Spazzapan S, Climent MA, Pavesi L, Ruhstaller T, Davidson NE, Coleman R, Debled M, Buchholz S, Ingle JN, Winer EP, Maibach R, Rabaglio-Poretti M, Ruepp B, Di Leo A, Coates AS, Gelber RD, Goldhirsch A, Regan MMThe New England journal of medicineTailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. N Engl J Med. 2018 Jul 12; 379(2):122-137.N Engl J Med2018-06-04T00:00:002018Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.17614302Burstein HJ, Keshaviah A, Baron AD, Hart RD, Lambert-Falls R, Marcom PK, Gelman R, Winer EPCancerTrastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer. 2007 Sep 01; 110(5):965-72.Cancer2007-09-01T00:00:002007Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study.Authorship 107401912149306Winer EP, Hudis C, Burstein HJ, Chlebowski RT, Ingle JN, Edge SB, Mamounas EP, Gralow J, Goldstein LJ, Pritchard KI, Braun S, Cobleigh MA, Langer AS, Perotti J, Powles TJ, Whelan TJ, Browman GPJournal of clinical oncology : official journal of the American Society of Clinical OncologyAmerican Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. J Clin Oncol. 2002 Aug 01; 20(15):3317-27.J Clin Oncol2002-08-01T00:00:002002American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002.23221783Burstein HJJournal of the National Comprehensive Cancer Network : JNCCNMeasuring hope: patient expectations of chemotherapy for advanced cancer. J Natl Compr Canc Netw. 2012 Dec 01; 10(12):1459-60.J Natl Compr Canc Netw2012-12-01T00:00:002012Measuring hope: patient expectations of chemotherapy for advanced cancer.22294487Wu AH, Lorizio W, Tchu S, Lynch K, Gerona R, Ji W, Ruan W, Ruddy KJ, Desantis SD, Burstein HJ, Ziv EBreast cancer research and treatmentEstimation of tamoxifen metabolite concentrations in the blood of breast cancer patients through CYP2D6 genotype activity score. Breast Cancer Res Treat. 2012 Jun; 133(2):677-83.Breast Cancer Res Treat2012-06-01T00:00:002012Estimation of tamoxifen metabolite concentrations in the blood of breast cancer patients through CYP2D6 genotype activity score.22491041Burstein HJJournal of the National Comprehensive Cancer Network : JNCCNIf the choices are all the same, why not prefer the less-expensive option? J Natl Compr Canc Netw. 2012 Apr; 10(4):425-6.J Natl Compr Canc Netw2012-04-01T00:00:002012If the choices are all the same, why not prefer the less-expensive option?16507275Carlson RW, Brown E, Burstein HJ, Gradishar WJ, Hudis CA, Loprinzi C, Mamounas EP, Perez EA, Pritchard K, Ravdin P, Recht A, Somlo G, Theriault RL, Winer EP, Wolff ACJournal of the National Comprehensive Cancer Network : JNCCNNCCN Task Force Report: Adjuvant Therapy for Breast Cancer. J Natl Compr Canc Netw. 2006 Mar; 4 Suppl 1:S1-26.J Natl Compr Canc Netw2006-03-01T00:00:002006NCCN Task Force Report: Adjuvant Therapy for Breast Cancer.17509259Podoloff DA, Advani RH, Allred C, Benson AB, Brown E, Burstein HJ, Carlson RW, Coleman RE, Czuczman MS, Delbeke D, Edge SB, Ettinger DS, Grannis FW, Hillner BE, Hoffman JM, Kiel K, Komaki R, Larson SM, Mankoff DA, Rosenzweig KE, Skibber JM, Yahalom J, Yu JM, Zelenetz ADJournal of the National Comprehensive Cancer Network : JNCCNNCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer. J Natl Compr Canc Netw. 2007 May; 5 Suppl 1:S1-22; quiz S23-2.J Natl Compr Canc Netw2007-05-01T00:00:002007NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer.19209136Burstein HClinical advances in hematology & oncology : H&OUpdates in anti-HER2 combination therapy. Clin Adv Hematol Oncol. 2008 Dec; 6(12):873-4.Clin Adv Hematol Oncol2008-12-01T00:00:002008Updates in anti-HER2 combination therapy.19460277Burstein HJJournal of the National Comprehensive Cancer Network : JNCCNDo clinical trials belong in clinical guidelines? J Natl Compr Canc Netw. 2009 May; 7(5):489.J Natl Compr Canc Netw2009-05-01T00:00:002009Do clinical trials belong in clinical guidelines?20947719Burstein HJJournal of the National Comprehensive Cancer Network : JNCCNAddressing oncology pharmacy & policy. J Natl Compr Canc Netw. 2010 Sep; 8 Suppl 7:S1.J Natl Compr Canc Netw2010-09-01T00:00:002010Addressing oncology pharmacy & policy.22308511Burstein HJJournal of the National Comprehensive Cancer Network : JNCCNDisclosing pharma payments to oncologists: what will we learn? J Natl Compr Canc Netw. 2012 Feb; 10(2):133-4.J Natl Compr Canc Netw2012-02-01T00:00:002012Disclosing pharma payments to oncologists: what will we learn?23054871Burstein HJJournal of the National Comprehensive Cancer Network : JNCCNAssuring access to academic cancer centers. J Natl Compr Canc Netw. 2012 Oct 01; 10(10):1177-8.J Natl Compr Canc Netw2012-10-01T00:00:002012Assuring access to academic cancer centers.19241643Burstein HJJournal of the National Comprehensive Cancer Network : JNCCNPersonalized medicine and breast cancer care. J Natl Compr Canc Netw. 2009 Feb; 7(2):109.J Natl Compr Canc Netw2009-02-01T00:00:002009Personalized medicine and breast cancer care.19608616Beslija S, Bonneterre J, Burstein HJ, Cocquyt V, Gnant M, Heinemann V, Jassem J, Köstler WJ, Krainer M, Menard S, Petit T, Petruzelka L, Possinger K, Schmid P, Stadtmauer E, Stockler M, Van Belle S, Vogel C, Wilcken N, Wiltschke C, Zielinski CC, Zwierzina HAnnals of oncology : official journal of the European Society for Medical OncologyThird consensus on medical treatment of metastatic breast cancer. Ann Oncol. 2009 Nov; 20(11):1771-85.Ann Oncol2009-07-16T00:00:002009Third consensus on medical treatment of metastatic breast cancer.19635224Burstein HJJournal of the National Comprehensive Cancer Network : JNCCNQuality measures, clinical practice, NCCN, and McAllen, Texas. J Natl Compr Canc Netw. 2009 Jul; 7(7):695.J Natl Compr Canc Netw2009-07-01T00:00:002009Quality measures, clinical practice, NCCN, and McAllen, Texas.20142587Burstein HJ, Sun Y, Dirix LY, Jiang Z, Paridaens R, Tan AR, Awada A, Ranade A, Jiao S, Schwartz G, Abbas R, Powell C, Turnbull K, Vermette J, Zacharchuk C, Badwe RJournal of clinical oncology : official journal of the American Society of Clinical OncologyNeratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol. 2010 Mar 10; 28(8):1301-7.J Clin Oncol2010-02-08T00:00:002010Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.21600381Burstein HJSeminars in oncologyNovel agents and future directions for refractory breast cancer. Semin Oncol. 2011 Jun; 38 Suppl 2:S17-24.Semin Oncol2011-06-01T00:00:002011Novel agents and future directions for refractory breast cancer.Authorship 10899281530146695Hurria A, Soto-Perez-de-Celis E, Allred JB, Cohen HJ, Arsenyan A, Ballman K, Le-Rademacher J, Jatoi A, Filo J, Mandelblatt J, Lafky JM, Kimmick G, Klepin HD, Freedman RA, Burstein H, Gralow J, Wolff AC, Magrinat G, Barginear M, Muss HJournal of the American Geriatrics SocietyFunctional Decline and Resilience in Older Women Receiving Adjuvant Chemotherapy for Breast Cancer. J Am Geriatr Soc. 2019 05; 67(5):920-927.J Am Geriatr Soc2018-08-26T00:00:002018Functional Decline and Resilience in Older Women Receiving Adjuvant Chemotherapy for Breast Cancer.Authorship 1091914230193367Rini BI, Burstein HJ, George DJJAMA oncologyInformation Transparency in the Drug Approval Process. JAMA Oncol. 2018 11 01; 4(11):1621-1622.JAMA Oncol2018-11-01T00:00:002018Information Transparency in the Drug Approval Process.Authorship 119060120971837Burstein HJJournal of the National Comprehensive Cancer Network : JNCCNBoard recertification. J Natl Compr Canc Netw. 2010 Oct; 8(10):1111.J Natl Compr Canc Netw2010-10-01T00:00:002010Board recertification.21357661Burstein HJJournal of the National Comprehensive Cancer Network : JNCCNTake your medicine. J Natl Compr Canc Netw. 2011 Feb; 9 Suppl 3:S1.J Natl Compr Canc Netw2011-02-01T00:00:002011Take your medicine.22773798Carlson RW, Allred DC, Anderson BO, Burstein HJ, Edge SB, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Smith ML, Soliman H, Somlo G, Theriault RL, Ward JH, Wolff AC, Zellars R, Kumar R, Shead DAJournal of the National Comprehensive Cancer Network : JNCCNMetastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012 Jul 01; 10(7):821-9.J Natl Compr Canc Netw2012-07-01T00:00:002012Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines.19755042Stubblefield MD, Burstein HJ, Burton AW, Custodio CM, Deng GE, Ho M, Junck L, Morris GS, Paice JA, Tummala S, Von Roenn JHJournal of the National Comprehensive Cancer Network : JNCCNNCCN task force report: management of neuropathy in cancer. J Natl Compr Canc Netw. 2009 Sep; 7 Suppl 5:S1-S26; quiz S27-8.J Natl Compr Canc Netw2009-09-01T00:00:002009NCCN task force report: management of neuropathy in cancer.21205755Choueiri TK, Mayer EL, Je Y, Rosenberg JE, Nguyen PL, Azzi GR, Bellmunt J, Burstein HJ, Schutz FAJournal of clinical oncology : official journal of the American Society of Clinical OncologyCongestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol. 2011 Feb 20; 29(6):632-8.J Clin Oncol2011-01-04T00:00:002011Congestive heart failure risk in patients with breast cancer treated with bevacizumab.21600379Burstein HJSeminars in oncologyIntroduction: Current and future approaches to chemotherapy in patients with resistant breast cancer. Semin Oncol. 2011 Jun; 38 Suppl 2:S1-2.Semin Oncol2011-06-01T00:00:002011Introduction: Current and future approaches to chemotherapy in patients with resistant breast cancer.23138159Burstein HJJournal of the National Comprehensive Cancer Network : JNCCNA "shot heard 'round the world" on cancer drug costs? J Natl Compr Canc Netw. 2012 Nov 01; 10(11):1315-6.J Natl Compr Canc Netw2012-11-01T00:00:002012A "shot heard 'round the world" on cancer drug costs?EM285ElizabethMittendorfElizabeth Mittendorf, M.D., Ph.D.172609Mittendorf, ElizabethProfessor of Surgery16831851Beslija S, Bonneterre J, Burstein H, Cocquyt V, Gnant M, Goodwin P, Heinemann V, Jassem J, Köstler WJ, Krainer M, Menard S, Petit T, Petruzelka L, Possinger K, Schmid P, Stadtmauer E, Stockler M, Van Belle S, Vogel C, Wilcken N, Wiltschke C, Zielinski CC, Zwierzina HAnnals of oncology : official journal of the European Society for Medical OncologySecond consensus on medical treatment of metastatic breast cancer. Ann Oncol. 2007 Feb; 18(2):215-25.Ann Oncol2006-07-10T00:00:002006Second consensus on medical treatment of metastatic breast cancer.17439759Mayer EL, Lin NU, Burstein HJJournal of the National Comprehensive Cancer Network : JNCCNNovel approaches to advanced breast cancer: bevacizumab and lapatinib. J Natl Compr Canc Netw. 2007 Mar; 5(3):314-23.J Natl Compr Canc Netw2007-03-01T00:00:002007Novel approaches to advanced breast cancer: bevacizumab and lapatinib.Authorship 12905229215850Burstein HJ, Janicek MJ, Skarin ATJournal of clinical oncology : official journal of the American Society of Clinical OncologyHypertrophic osteoarthropathy. J Clin Oncol. 1997 Jul; 15(7):2759-60.J Clin Oncol1997-07-01T00:00:001997Hypertrophic osteoarthropathy.Authorship 1108591230357308Metzger Filho O, Burstein HJAnnals of oncology : official journal of the European Society for Medical OncologyDuration of adjuvant trastuzumab: might less be more? Ann Oncol. 2018 12 01; 29(12):2273-2274.Ann Oncol2018-12-01T00:00:002018Duration of adjuvant trastuzumab: might less be more?20620932Burstein HJ, Griggs JJSurgical oncology clinics of North AmericaAdjuvant hormonal therapy for early-stage breast cancer. Surg Oncol Clin N Am. 2010 Jul; 19(3):639-47.Surg Oncol Clin N Am2010-05-26T00:00:002010Adjuvant hormonal therapy for early-stage breast cancer.Authorship 1113298130452337Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KA, Giordano SH, Hudis CA, Solky AJ, Stearns V, Winer EP, Griggs JJJournal of clinical oncology : official journal of the American Society of Clinical OncologyAdjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. J Clin Oncol. 2019 02 10; 37(5):423-438.J Clin Oncol2018-11-19T00:00:002018Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update.17512448Mayer EL, Burstein HJHematology/oncology clinics of North AmericaChemotherapy for metastatic breast cancer. Hematol Oncol Clin North Am. 2007 Apr; 21(2):257-72.Hematol Oncol Clin North Am2007-04-01T00:00:002007Chemotherapy for metastatic breast cancer.17719225Burstein HJBreast (Edinburgh, Scotland)Cognitive side-effects of adjuvant treatments. Breast. 2007 Dec; 16 Suppl 2:S166-8.Breast2007-08-23T00:00:002007Cognitive side-effects of adjuvant treatments.21383305Burstein HJJournal of clinical oncology : official journal of the American Society of Clinical OncologyBevacizumab for advanced breast cancer: all tied up with a RIBBON? J Clin Oncol. 2011 Apr 01; 29(10):1232-5.J Clin Oncol2011-03-07T00:00:002011Bevacizumab for advanced breast cancer: all tied up with a RIBBON?22773794Burstein HJJournal of the National Comprehensive Cancer Network : JNCCNSimplifying guidelines: we only need one adjuvant chemotherapy regimen for breast cancer. J Natl Compr Canc Netw. 2012 Jul 01; 10(7):797-8.J Natl Compr Canc Netw2012-07-01T00:00:002012Simplifying guidelines: we only need one adjuvant chemotherapy regimen for breast cancer.22956802Burstein HJJournal of the National Comprehensive Cancer Network : JNCCNPathway-based oncology care: time for more transparency. J Natl Compr Canc Netw. 2012 Sep; 10(9):1043-4.J Natl Compr Canc Netw2012-09-01T00:00:002012Pathway-based oncology care: time for more transparency.Authorship 109258123032626Bellon JR, Wong JS, Burstein HJJournal of clinical oncology : official journal of the American Society of Clinical OncologyShould response to preoperative chemotherapy affect radiotherapy recommendations after mastectomy for stage II breast cancer? J Clin Oncol. 2012 Nov 10; 30(32):3916-20.J Clin Oncol2012-10-01T00:00:002012Should response to preoperative chemotherapy affect radiotherapy recommendations after mastectomy for stage II breast cancer?Authorship 1123323330601740DeFilippis EM, Nohria A, Burstein HJ, Doyle LA, Miller AL, Loscalzo JThe New England journal of medicineA Breath-Taking Diagnosis. N Engl J Med. 2019 01 03; 380(1):81-87.N Engl J Med2019-01-03T00:00:002019A Breath-Taking Diagnosis.10352166Burstein HJ, Gelber S, Guadagnoli E, Weeks JCThe New England journal of medicineUse of alternative medicine by women with early-stage breast cancer. N Engl J Med. 1999 Jun 03; 340(22):1733-9.N Engl J Med1999-06-03T00:00:001999Use of alternative medicine by women with early-stage breast cancer.10893279Burstein HJJournal of clinical oncology : official journal of the American Society of Clinical OncologyDiscussing complementary therapies with cancer patients: what should we be talking about? J Clin Oncol. 2000 Jul; 18(13):2501-4.J Clin Oncol2000-07-01T00:00:002000Discussing complementary therapies with cancer patients: what should we be talking about?16002000Carlson RW, Anderson BO, Burstein HJ, Cox CE, Edge SB, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis C, Jahanzeb M, Ljung BM, Marks LB, McCormick B, Nabell LM, Pierce LJ, Reed EC, Silver SM, Smith ML, Somlo G, Theriault RL, Ward JH, Winer EP, Wolff ACJournal of the National Comprehensive Cancer Network : JNCCNBreast cancer. J Natl Compr Canc Netw. 2005 May; 3(3):238-89.J Natl Compr Canc Netw2005-05-01T00:00:002005Breast cancer.16150805Burstein HJ, Lieberman G, Slamon DJ, Winer EP, Klein PAnnals of oncology : official journal of the European Society for Medical OncologyIsolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann Oncol. 2005 Nov; 16(11):1772-7.Ann Oncol2005-09-08T00:00:002005Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy.Authorship 11240598Authorship 11247031Authorship 1124659230624581Wu Y, Amonkar MM, Sherrill BH, O'Shaughnessy J, Ellis C, Baselga J, Blackwell KL, Burstein HJAnnals of oncology : official journal of the European Society for Medical OncologyImpact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer. Ann Oncol. 2019 06 01; 30(6):1019.Ann Oncol2019-06-01T00:00:002019Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer.30624592Curigliano G, Burstein HJ, P Winer E, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann BAnnals of oncology : official journal of the European Society for Medical OncologyDe-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2019 07 01; 30(7):1181.Ann Oncol2019-07-01T00:00:002019De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.14179983BURSTEIN HJSkinMAMMARY PAGET'S DISEASE. Skin (Los Angeles). 1964 Jul; 3:206-11.Skin (Los Angeles)1964-07-01T00:00:001964MAMMARY PAGET'S DISEASE.19047116Burstein HJ, Chen YH, Parker LM, Savoie J, Younger J, Kuter I, Ryan PD, Garber JE, Chen H, Campos SM, Shulman LN, Harris LN, Gelman R, Winer EPClinical cancer research : an official journal of the American Association for Cancer ResearchVEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res. 2008 Dec 01; 14(23):7871-7.Clin Cancer Res2008-12-01T00:00:002008VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy.Authorship 10681113777858Dohnal JC, Bowie LJ, Burstein HJAnnals of clinical and laboratory scienceFunctional phospholipid/sphingomyelin ratio: an easy to interpret indicator of fetal lung maturity. Ann Clin Lab Sci. 1986 Sep-Oct; 16(5):407-11.Ann Clin Lab Sci1986-09-01T00:00:001986Functional phospholipid/sphingomyelin ratio: an easy to interpret indicator of fetal lung maturity.Authorship 1132178130523754Burstein HJ, Lacchetti C, Griggs JJJournal of oncology practiceAdjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. J Oncol Pract. 2019 Feb; 15(2):106-107.J Oncol Pract2018-12-05T00:00:002018Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update.2025-02-28BURSTEIN, HAROLD JOHN ;KIBEL, ADAM S;RYAN, DAVID P2019-03-05NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer CareUG1CA233180Principal InvestigatorAuthorship 1136267830787125Goetz MP, Gradishar WJ, Anderson BO, Abraham J, Aft R, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Farrar WB, Giordano SH, Goldstein LJ, Isakoff SJ, Lyons J, Marcom PK, Mayer IA, Moran MS, Mortimer J, O'Regan RM, Patel SA, Pierce LJ, Reed EC, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Telli ML, Ward JH, Young JS, Shead DA, Kumar RJournal of the National Comprehensive Cancer Network : JNCCNNCCN Guidelines Insights: Breast Cancer, Version 3.2018. J Natl Compr Canc Netw. 2019 02; 17(2):118-126.J Natl Compr Canc Netw2019-02-01T00:00:002019NCCN Guidelines Insights: Breast Cancer, Version 3.2018.D001943Disorders2830206760.141753Breast NeoplasmsD018719Chemicals & Drugs65223700.47981Receptor, erbB-2Authorship 1455313D000971Procedures1751114100.225091Antineoplastic Combined Chemotherapy ProtocolsD047072Chemicals & Drugs1624900.728109Aromatase InhibitorsAuthorship 114201625Authorship 11428031731004299Bellon JR, Guo H, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Hudis CA, Krop I, Burstein HJ, Winer EP, Tolaney SMBreast cancer research and treatmentLocal-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial). Breast Cancer Res Treat. 2019 Jul; 176(2):303-310.Breast Cancer Res Treat2019-04-19T00:00:002019Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial).30939096Tolaney SM, Guo H, Pernas S, Barry WT, Dillon DA, Ritterhouse L, Schneider BP, Shen F, Fuhrman K, Baltay M, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Overmoyer B, Partridge AH, Hudis CA, Krop IE, Burstein HJ, Winer EPJournal of clinical oncology : official journal of the American Society of Clinical OncologySeven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. J Clin Oncol. 2019 08 01; 37(22):1868-1875.J Clin Oncol2019-04-02T00:00:002019Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.D018931Chemicals & Drugs45214970.530951Antineoplastic Agents, HormonalMedicinePMESurgeryHematology/OncologyOncologyBrigham and Women's HospitalDana-Farber Cancer InstituteHarvard Medical SchoolMassachusetts General HospitalNUL1NancyLinNancy U. Lin, M.D.42.33789600000000-71.1072493000000033284Lin, NancyAssociate Professor of MedicineAHP1AnnPartridgeAnn Hart Partridge, M.D.42.33789600000000-71.1072493000000084598Partridge, AnnProfessor of MedicineAuthorship 11552822Authorship 1154583131099622Litton JK, Burstein HJ, Turner NCAmerican Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual MeetingMolecular Testing in Breast Cancer. Am Soc Clin Oncol Educ Book. 2019 Jan; 39:e1-e7.Am Soc Clin Oncol Educ Book2019-05-17T00:00:002019Molecular Testing in Breast Cancer.31094498Burstein HJJournal of the National Comprehensive Cancer Network : JNCCNTake Your Medicine J Natl Compr Canc Netw. 2011 Feb 01; 9(9 Suppl 3):S1.J Natl Compr Canc Netw2011-02-01T00:00:002011Take Your MedicineRSG4RebeccaGelmanRebecca Sue Gelman, Ph.D.42.33789600000000-71.1072493000000034853Gelman, RebeccaAssociate Professor of MedicineDCF4DavidFisherDavid Christopher Fisher, M.D.42.33789600000000-71.1072493000000062220Fisher, DavidAssistant Professor of MedicineXL4XiaoyuLiXiaoyu Li, M.D., Ph.D.42.33789600000000-71.107249300000004398Li, XiaoyuResearch Associate in MedicineELW2EllenWeisbergEllen L. Weisberg, Ph.D.42.33789600000000-71.1072493000000039026Weisberg, EllenPrincipal Associate in MedicinePEG5PaulGossPaul E. Goss, M.B.,B.Ch., Ph.D.42.36241700000000-71.0689370000000042847Goss, PaulProfessor of MedicineAAW7AlexiWrightAlexi Anne Wright, M.D.42.33789600000000-71.1072493000000038097Wright, AlexiAssociate Professor of MedicineEPW2EricWinerEric Paul Winer, M.D.42.33789600000000-71.107249300000005538Winer, EricProfessor of Medicine, EmeritusSMT9SaraTolaneySara Michell Tolaney, M.D.42.33789600000000-71.1072493000000067909Tolaney, SaraAssociate Professor of MedicineAuthorship 137380111337selected publications9.214890.00404296611research areas10.09990.013775192coauthor of392.6553.543360similar toAuthorship 11665811531250880Mayer EL, DeMichele A, Rugo HS, Miller K, Waks AG, Come SE, Mulvey T, Jeselsohn R, Overmoyer B, Guo H, Barry WT, Huang Bartlett C, Koehler M, Winer EP, Burstein HJAnnals of oncology : official journal of the European Society for Medical OncologyA phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma. Ann Oncol. 2019 09 01; 30(9):1514-1520.Ann Oncol2019-09-01T00:00:002019A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma.Authorship 11742721631339827Muss HB, Polley MC, Berry DA, Liu H, Cirrincione CT, Theodoulou M, Mauer AM, Kornblith AB, Partridge AH, Dressler LG, Cohen HJ, Kartcheske PA, Perez EA, Wolff AC, Gralow JR, Burstein HJ, Mahmood AA, Sutton LM, Magrinat G, Parker BA, Hart RD, Grenier D, Hurria A, Jatoi A, Norton L, Hudis CA, Winer EP, Carey LJournal of clinical oncology : official journal of the American Society of Clinical OncologyRandomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial. J Clin Oncol. 2019 09 10; 37(26):2338-2348.J Clin Oncol2019-07-24T00:00:002019Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial.Authorship 1178211131373601Burstein HJ, Curigliano G, Loibl S, Dubsky P, Gnant M, Poortmans P, Colleoni M, Denkert C, Piccart-Gebhart M, Regan M, Senn HJ, Winer EP, Thurlimann BAnnals of oncology : official journal of the European Society for Medical OncologyEstimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol. 2019 10 01; 30(10):1541-1557.Ann Oncol2019-10-01T00:00:002019Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019.Authorship 1155813true1Assistant Professor of MedicineAssistant Professor of Medicinetrue1Professor of MedicineProfessor of Medicinetrue1Associate Professor of MedicineAssociate Professor of Medicinetrue1Principal Associate in MedicinePrincipal Associate in Medicinetrue1Professor of MedicineProfessor of Medicinetrue1Research Associate in MedicineResearch Associate in Medicinetrue1Associate Professor of MedicineAssociate Professor of MedicineAuthorship 1211674131839170Burstein HJBreast (Edinburgh, Scotland)Adjuvant endocrine therapy in postmenopausal women: making treatment choices based on the magnitude of benefit. Breast. 2019 Nov; 48 Suppl 1:S89-S91.Breast2019-11-01T00:00:002019Adjuvant endocrine therapy in postmenopausal women: making treatment choices based on the magnitude of benefit.Authorship 1373221Authorship 1511964Authorship 12222022Authorship 122180015Authorship 1222252131987407Mayer EL, DeMichele A, Rugo HS, Miller K, Waks AG, Come SE, Mulvey T, Jeselsohn R, Overmoyer B, Guo H, Barry WT, Huang Bartlett C, Koehler M, Winer EP, Burstein HJAnnals of oncology : official journal of the European Society for Medical OncologyA phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma. Ann Oncol. 2019 Sep; 30(9):1514-1520.Ann Oncol2019-12-12T00:00:002019A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma.31987446Burstein HJ, Curigliano G, Loibl S, Dubsky P, Gnant M, Poortmans P, Colleoni M, Denkert C, Piccart-Gebhart M, Regan M, Senn HJ, Winer EP, Thurlimann BAnnals of oncology : official journal of the European Society for Medical OncologyEstimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol. 2019 Oct; 30(10):1541-1557.Ann Oncol2019-12-27T00:00:002019Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019.31987391Curigliano G, Burstein HJ, P Winer E, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann BAnnals of oncology : official journal of the European Society for Medical OncologyCorrections to "De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017". Ann Oncol. 2019 Jul; 30(7):1181.Ann Oncol2019-12-04T00:00:002019Corrections to "De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017".Authorship 1222843732018392Olson EM, Lin NU, DiPiro PJ, Najita JS, Krop IE, Winer EP, Burstein HJAnnals of oncology : official journal of the European Society for Medical OncologyResponses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer. Ann Oncol. 2012 Jan; 23(1):93-97.Ann Oncol2019-12-04T00:00:002019Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer.true1Professor of SurgeryProfessor of SurgeryAuthorship 1234320332185586Hassett MJ, Li H, Burstein HJ, Punglia RSBreast cancer research and treatmentNeoadjuvant treatment strategies for HER2-positive breast cancer: cost-effectiveness and quality of life outcomes. Breast Cancer Res Treat. 2020 May; 181(1):43-51.Breast Cancer Res Treat2020-03-17T00:00:002020Neoadjuvant treatment strategies for HER2-positive breast cancer: cost-effectiveness and quality of life outcomes.Authorship 1235659932217075Gelber RD, Coates AS, Gelber S, Orecchia R, Veronesi P, Di Leo A, Colleoni M, Winer EP, Burstein HJ, Viale G, Senn HJ, Piccart M, Curigliano GAnnals of oncology : official journal of the European Society for Medical OncologyThe legacy of Professor Aron Goldhirsch. Ann Oncol. 2020 06; 31(6):671-673.Ann Oncol2020-03-23T00:00:002020The legacy of Professor Aron Goldhirsch.Authorship 12393508Authorship 1239179432274665Ribi K, Luo W, Walley BA, Burstein HJ, Chirgwin J, Ansari RH, Salim M, van der Westhuizen A, Abdi E, Francis PA, Chia S, Harvey VJ, Giobbie-Hurder A, Fleming GF, Pagani O, Di Leo A, Colleoni M, Gelber RD, Goldhirsch A, Coates AS, Regan MM, Bernhard JBreast cancer research and treatmentTreatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy. Breast Cancer Res Treat. 2020 Jun; 181(2):347-359.Breast Cancer Res Treat2020-04-09T00:00:002020Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy.32259783Gradishar WJ, Anderson BO, Abraham J, Aft R, Agnese D, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Krishnamurthy J, Lyons J, Marcom PK, Matro J, Mayer IA, Moran MS, Mortimer J, O'Regan RM, Patel SA, Pierce LJ, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Ward JH, Young JS, Burns JL, Kumar RJournal of the National Comprehensive Cancer Network : JNCCNBreast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 04; 18(4):452-478.J Natl Compr Canc Netw2020-04-01T00:00:002020Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.32330102Vaz-Luis I, Barroso-Sousa R, Di Meglio A, Hu J, Rees R, Sinclair N, Milisits L, Leone JP, Constantine M, Faggen M, Briccetti F, Block C, O'Neil K, Partridge A, Burstein H, Waks AG, Trippa L, Tolaney SM, Hassett M, Winer EP, Lin NUJournal of clinical oncology : official journal of the American Society of Clinical OncologyAvoiding Peg-Filgrastim Prophylaxis During the Paclitaxel Portion of the Dose-Dense Doxorubicin-Cyclophosphamide and Paclitaxel Regimen: A Prospective Study. J Clin Oncol. 2020 07 20; 38(21):2390-2397.J Clin Oncol2020-04-24T00:00:002020Avoiding Peg-Filgrastim Prophylaxis During the Paclitaxel Portion of the Dose-Dense Doxorubicin-Cyclophosphamide and Paclitaxel Regimen: A Prospective Study.32333293Dietz JR, Moran MS, Isakoff SJ, Kurtzman SH, Willey SC, Burstein HJ, Bleicher RJ, Lyons JA, Sarantou T, Baron PL, Stevens RE, Boolbol SK, Anderson BO, Shulman LN, Gradishar WJ, Monticciolo DL, Plecha DM, Nelson H, Yao KABreast cancer research and treatmentRecommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium. Breast Cancer Res Treat. 2020 Jun; 181(3):487-497.Breast Cancer Res Treat2020-04-24T00:00:002020Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium.Authorship 124025415Authorship 12423576Authorship 1731101Authorship 1301371Authorship 14145916Authorship 1456337Authorship 1413801Authorship 1548473Authorship 1622253Authorship 1830273Authorship 1831071Authorship 12764532632770247Magbanua MJM, Hendrix LH, Hyslop T, Barry WT, Winer EP, Hudis C, Toppmeyer D, Carey LA, Partridge AH, Pierga JY, Fehm T, Vidal-Martínez J, Mavroudis D, Garcia-Saenz JA, Stebbing J, Gazzaniga P, Manso L, Zamarchi R, Antelo ML, Mattos-Arruda L, Generali D, Caldas C, Munzone E, Dirix L, Delson AL, Burstein HJ, Qadir M, Ma C, Scott JH, Bidard FC, Park JW, Rugo HSJournal of the National Cancer InstituteSerial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy. J Natl Cancer Inst. 2021 04 06; 113(4):443-452.J Natl Cancer Inst2021-04-06T00:00:002021Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy.Authorship 1878681true1Associate Professor of MedicineAssociate Professor of MedicineAuthorship 1290951232986241Bellon JR, Burstein HJ, Frank ES, Mittendorf EA, King TACA: a cancer journal for cliniciansMultidisciplinary considerations in the treatment of triple-negative breast cancer. CA Cancer J Clin. 2020 11; 70(6):432-442.CA Cancer J Clin2020-09-28T00:00:002020Multidisciplinary considerations in the treatment of triple-negative breast cancer.Authorship 12932591133025482Filho OM, Giobbie-Hurder A, Lin NU, Faggen M, Come S, Openshaw T, Constantine M, Walsh J, Freedman RA, Schneider B, Burstein HJ, Mayer ELBreast cancer research and treatmentA dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer. Breast Cancer Res Treat. 2021 Jan; 185(1):135-144.Breast Cancer Res Treat2020-10-06T00:00:002020A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer.33300953Parsons HA, Burstein HJJAMAAdjuvant Capecitabine in Triple-Negative Breast Cancer: New Strategies for Tailoring Treatment Recommendations. JAMA. 2021 01 05; 325(1):36-38.JAMA2021-01-05T00:00:002021Adjuvant Capecitabine in Triple-Negative Breast Cancer: New Strategies for Tailoring Treatment Recommendations.Authorship 13125142Authorship 1315421133369357Burstein HJThe New England journal of medicineSystemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer. N Engl J Med. 2020 12 24; 383(26):2557-2570.N Engl J Med2020-12-24T00:00:002020Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer.Authorship 1322267533460574Mayer EL, Dueck AC, Martin M, Rubovszky G, Burstein HJ, Bellet-Ezquerra M, Miller KD, Zdenkowski N, Winer EP, Pfeiler G, Goetz M, Ruiz-Borrego M, Anderson D, Nowecki Z, Loibl S, Moulder S, Ring A, Fitzal F, Traina T, Chan A, Rugo HS, Lemieux J, Henao F, Lyss A, Antolin Novoa S, Wolff AC, Vetter M, Egle D, Morris PG, Mamounas EP, Gil-Gil MJ, Prat A, Fohler H, Metzger Filho O, Schwarz M, DuFrane C, Fumagalli D, Theall KP, Lu DR, Bartlett CH, Koehler M, Fesl C, DeMichele A, Gnant MThe Lancet. OncologyPalbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2021 02; 22(2):212-222.Lancet Oncol2021-01-15T00:00:002021Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study.Authorship 1323274433502535Trapani D, Douillard JY, Winer EP, Burstein H, Carey LA, Cortes J, Lopes G, Gralow JR, Gradishar WJ, Magrini N, Curigliano G, Ilbawi AMJournal of the National Cancer InstituteThe Global Landscape of Treatment Standards for Breast Cancer. J Natl Cancer Inst. 2021 09 04; 113(9):1143-1155.J Natl Cancer Inst2021-09-04T00:00:002021The Global Landscape of Treatment Standards for Breast Cancer.Authorship 2023161Authorship 1341430133761226Burstein HJThe New England journal of medicineSystemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer. Reply. N Engl J Med. 2021 03 25; 384(12):1176-1177.N Engl J Med2021-03-25T00:00:002021Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer. Reply.Authorship 13560687Authorship 1356727434010423Kantor O, King TA, Shak S, Russell CA, Giuliano AE, Hortobagyi GN, Burstein HJ, Winer EP, Dey T, Sparano JA, Mittendorf EAJournal of the National Cancer InstituteExpanding Criteria for Prognostic Stage IA in Hormone Receptor-Positive Breast Cancer. J Natl Cancer Inst. 2021 Nov 29; 113(12):1744-1750.J Natl Cancer Inst2021-11-29T00:00:002021Expanding Criteria for Prognostic Stage IA in Hormone Receptor-Positive Breast Cancer.33981951Ligibel JA, Huebner L, Rugo HS, Burstein HJ, Toppmeyer DL, Anders CK, Ma C, Barry WT, Suman V, Carey LA, Partridge AH, Hudis CA, Winer EPJNCI cancer spectrumPhysical Activity, Weight, and Outcomes in Patients Receiving Chemotherapy for Metastatic Breast Cancer (C40502/Alliance). JNCI Cancer Spectr. 2021 06; 5(3).JNCI Cancer Spectr2021-04-12T00:00:002021Physical Activity, Weight, and Outcomes in Patients Receiving Chemotherapy for Metastatic Breast Cancer (C40502/Alliance).Authorship 1358370834030128Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Hurvitz SA, Isakoff SJ, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch M, Lyons J, Matro J, Mayer IA, Mortimer J, O'Regan RM, Patel SA, Pierce LJ, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Ward JH, Wisinski KB, Young JS, Burns JL, Kumar RJournal of the National Comprehensive Cancer Network : JNCCNNCCN Guidelines® Insights: Breast Cancer, Version 4.2021. J Natl Compr Canc Netw. 2021 05 01; 19(5):484-493.J Natl Compr Canc Netw2021-05-01T00:00:002021NCCN Guidelines® Insights: Breast Cancer, Version 4.2021.Authorship 13610824434077270Tolaney SM, Tayob N, Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Hu J, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, Constantine M, Cheng K, Briccetti F, Schneider B, Garrett AM, Marcom K, Albain K, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu M, Ruddy K, Zheng Y, Rosenberg SM, Gelber RD, Trippa L, Barry W, DeMeo M, Burstein H, Partridge A, Winer EP, Krop IJournal of clinical oncology : official journal of the American Society of Clinical OncologyAdjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. J Clin Oncol. 2021 07 20; 39(21):2375-2385.J Clin Oncol2021-06-02T00:00:002021Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial.Authorship 13640104134120223Ruddy KJ, Zheng Y, Tayob N, Hu J, Dang CT, Yardley DA, Isakoff SJ, Valero VV, Faggen MG, Mulvey TM, Bose R, Sella T, Weckstein DJ, Wolff AC, Reeder-Hayes KE, Rugo HS, Ramaswamy B, Zuckerman DS, Hart LL, Gadi VK, Constantine M, Cheng KL, Briccetti FM, Schneider BP, Merrill Garrett A, Kelly Marcom P, Albain KS, DeFusco PA, Tung NM, Ardman BM, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu MC, Rosenberg S, DeMeo MK, Burstein HJ, Winer EP, Krop IE, Partridge AH, Tolaney SMBreast cancer research and treatmentChemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial). Breast Cancer Res Treat. 2021 Aug; 189(1):103-110.Breast Cancer Res Treat2021-06-12T00:00:002021Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial).Authorship 1372861134242744Burstein HJ, Curigliano G, Thürlimann B, Weber WP, Poortmans P, Regan MM, Senn HJ, Winer EP, Gnant MAnnals of oncology : official journal of the European Society for Medical OncologyCustomizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol. 2021 10; 32(10):1216-1235.Ann Oncol2021-07-06T00:00:002021Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021.Authorship 1378846134324367Burstein HJ, Somerfield MR, Barton DL, Dorris A, Fallowfield LJ, Jain D, Johnston SRD, Korde LA, Litton JK, Macrae ER, Peterson LL, Vikas P, Yung RL, Rugo HSJournal of clinical oncology : official journal of the American Society of Clinical OncologyEndocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update. J Clin Oncol. 2021 12 10; 39(35):3959-3977.J Clin Oncol2021-07-29T00:00:002021Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update.Authorship 13850712234384882Jerusalem G, Farah S, Courtois A, Chirgwin J, Aebi S, Karlsson P, Neven P, Hitre E, Graas MP, Simoncini E, Abdi E, Kamby C, Thompson A, Loibl S, Gavilá J, Kuroi K, Marth C, Müller B, O'Reilly S, Gombos A, Ruhstaller T, Burstein HJ, Rabaglio M, Ruepp B, Ribi K, Viale G, Gelber RD, Coates AS, Loi S, Goldhirsch A, Regan MM, Colleoni MAnnals of oncology : official journal of the European Society for Medical OncologyContinuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy. Ann Oncol. 2021 10; 32(10):1256-1266.Ann Oncol2021-08-10T00:00:002021Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy.Authorship 13909091534472667Barroso-Sousa R, Vaz-Luis I, Di Meglio A, Hu J, Li T, Rees R, Sinclair N, Milisits L, Leone JP, Constantine M, Faggen M, Briccetti F, Block C, Partridge A, Burstein H, Waks AG, Tayob N, Trippa L, Tolaney SM, Hassett MJ, Winer EP, Lin NUThe oncologistProspective Study Testing a Simplified Paclitaxel Premedication Regimen in Patients with Early Breast Cancer. Oncologist. 2021 11; 26(11):927-933.Oncologist2021-09-24T00:00:002021Prospective Study Testing a Simplified Paclitaxel Premedication Regimen in Patients with Early Breast Cancer.Authorship 1735681Authorship 1736721Authorship 1787393Authorship 1870973Authorship 2199343Authorship 1412810834794122Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Hurvitz SA, Isakoff SJ, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch M, Lyons J, Matro J, Mayer IA, Mortimer J, O'Regan RM, Patel SA, Pierce LJ, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Ward JH, Wisinski KB, Young JS, Burns JL, Kumar RJournal of the National Comprehensive Cancer Network : JNCCNNCCN Guidelines® Insights: Breast Cancer, Version 4.2021. J Natl Compr Canc Netw. 2021 05 01; 19(5):484-493.J Natl Compr Canc Netw2021-05-01T00:00:002021NCCN Guidelines® Insights: Breast Cancer, Version 4.2021.Authorship 14197241Authorship 1419934234942341Tarantino P, Burstein HJ, Lin NU, Krop IE, Winer EP, Schnitt SJ, Hamilton EP, Hurvitz SA, Rugo HS, Curigliano G, Tolaney SMAnnals of oncology : official journal of the European Society for Medical OncologyShould Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib? Ann Oncol. 2022 03; 33(3):234-238.Ann Oncol2021-12-20T00:00:002021Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib?34924252Burstein HJBreast (Edinburgh, Scotland)Unmet challenges in systemic therapy for early stage breast cancer. Breast. 2022 Mar; 62 Suppl 1:S67-S69.Breast2021-12-13T00:00:002021Unmet challenges in systemic therapy for early stage breast cancer.Authorship 14228498Authorship 1422194534990776Bellon JR, Tayob N, Yang DD, Tralins J, Dang CT, Isakoff SJ, DeMeo M, Burstein HJ, Partridge AH, Winer EP, Krop IE, Tolaney SMInternational journal of radiation oncology, biology, physicsLocal Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer. Int J Radiat Oncol Biol Phys. 2022 05 01; 113(1):117-124.Int J Radiat Oncol Biol Phys2022-01-03T00:00:002022Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer.34995105Mayer EL, Fesl C, Hlauschek D, Garcia-Estevez L, Burstein HJ, Zdenkowski N, Wette V, Miller KD, Balic M, Mayer IA, Cameron D, Winer EP, Ponce Lorenzo JJ, Lake D, Pristauz-Telsnigg G, Haddad TC, Shepherd L, Iwata H, Goetz M, Cardoso F, Traina TA, Sabanathan D, Breitenstein U, Ackerl K, Metzger Filho O, Zehetner K, Solomon K, El-Abed S, Theall KP, Lu DR, Dueck A, Gnant M, DeMichele AJournal of clinical oncology : official journal of the American Society of Clinical OncologyTreatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03). J Clin Oncol. 2022 02 10; 40(5):449-458.J Clin Oncol2022-01-07T00:00:002022Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03).Authorship 209184135173164Barroso-Sousa R, Tarantino P, Tayob N, Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Hu J, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, Constantine M, Cheng K, Briccetti F, Schneider B, Garrett AM, Marcom K, Albain K, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu M, Ruddy KJ, Zheng Y, Rosenberg SM, Gelber RD, Trippa L, Barry W, DeMeo M, Burstein H, Partridge A, Winer EP, Krop I, Tolaney SMNPJ breast cancerCardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. NPJ Breast Cancer. 2022 Feb 16; 8(1):18.NPJ Breast Cancer2022-02-16T00:00:002022Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial.Authorship 14511132Authorship 1452590335536015Harbeck N, Burstein HJ, Hurvitz SA, Johnston S, Vidal GACancerA look at current and potential treatment approaches for hormone receptor-positive, HER2-negative early breast cancer. Cancer. 2022 06 01; 128 Suppl 11:2209-2223.Cancer2022-06-01T00:00:002022A look at current and potential treatment approaches for hormone receptor-positive, HER2-negative early breast cancer.35550723Trapani D, Franzoi MA, Burstein HJ, Carey LA, Delaloge S, Harbeck N, Hayes DF, Kalinsky K, Pusztai L, Regan MM, Sestak I, Spanic T, Sparano J, Jezdic S, Cherny N, Curigliano G, Andre FAnnals of oncology : official journal of the European Society for Medical OncologyRisk-adapted modulation through de-intensification of cancer treatments: an ESMO classification. Ann Oncol. 2022 07; 33(7):702-712.Ann Oncol2022-05-09T00:00:002022Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification.Authorship 1725192Authorship 14630122Authorship 14660493Authorship 14635142Authorship 14681583Authorship 1466291835900648Kantor O, Burstein HJ, King TA, Shak S, Russell CA, Giuliano AE, Hortobagyi GN, Winer EP, Korde LA, Sparano JA, Mittendorf EAAnnals of surgical oncologyExpanding the Staging Criteria for T1-2N0 Hormone-Receptor Positive Breast Cancer Patients Enrolled in TAILORx. Ann Surg Oncol. 2022 Dec; 29(13):8016-8023.Ann Surg Oncol2022-07-27T00:00:002022Expanding the Staging Criteria for T1-2N0 Hormone-Receptor Positive Breast Cancer Patients Enrolled in TAILORx.35763229Kantor O, Weiss A, Burstein HJ, Mittendorf EA, King TAAnnals of surgical oncologySentinel Lymph Node Biopsy Alone is Adequate for Chemotherapy Decisions in Postmenopausal Early-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer with One to Three Positive Sentinel Lymph Nodes. Ann Surg Oncol. 2022 Nov; 29(12):7674-7682.Ann Surg Oncol2022-06-28T00:00:002022Sentinel Lymph Node Biopsy Alone is Adequate for Chemotherapy Decisions in Postmenopausal Early-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer with One to Three Positive Sentinel Lymph Nodes.35810227Kantor O, Weiss A, Burstein HJ, Mittendorf EA, King TAAnnals of surgical oncologyASO Visual Abstract: Sentinel Lymph Node Biopsy Alone is Adequate for Chemotherapy Decisions in Postmenopausal Early-Stage, Hormone-Receptor-Positive, HER2-Negative Breast Cancer with 1-3 Positive Sentinel Lymph Nodes. Ann Surg Oncol. 2022 Nov; 29(12):7683-7684.Ann Surg Oncol2022-11-01T00:00:002022ASO Visual Abstract: Sentinel Lymph Node Biopsy Alone is Adequate for Chemotherapy Decisions in Postmenopausal Early-Stage, Hormone-Receptor-Positive, HER2-Negative Breast Cancer with 1-3 Positive Sentinel Lymph Nodes.35714673Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, Anderson B, Burstein HJ, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Hurvitz SA, Isakoff SJ, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch M, Lyons J, Mortimer J, Patel SA, Pierce LJ, Rosenberger LH, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Ward JH, Wisinski KB, Young JS, Burns J, Kumar RJournal of the National Comprehensive Cancer Network : JNCCNBreast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 06; 20(6):691-722.J Natl Compr Canc Netw2022-06-01T00:00:002022Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.35902504Kantor O, Burstein HJ, King TA, Shak S, Russell CA, Giuliano AE, Hortobagyi GN, Winer EP, Korde LA, Sparano JA, Mittendorf EAAnnals of surgical oncologyASO Visual Abstract: Expanding Staging Criteria in T1-2N0 Hormone Receptor-Positive Breast Cancer Patients Enrolled in TAILORx. Ann Surg Oncol. 2022 Dec; 29(13):8024-8025.Ann Surg Oncol2022-12-01T00:00:002022ASO Visual Abstract: Expanding Staging Criteria in T1-2N0 Hormone Receptor-Positive Breast Cancer Patients Enrolled in TAILORx.Authorship 148491021Authorship 1492366636163163Freedman RA, Li T, Sedrak MS, Hopkins JO, Tayob N, Faggen MG, Sinclair NF, Chen WY, Parsons HA, Mayer EL, Lange PB, Basta AS, Perilla-Glen A, Lederman RI, Wong A, Tiwari A, McAllister SS, Mittendorf EA, Miller PG, Gibson CJ, Burstein HJJournal of geriatric oncology'ADVANCE' (a pilot trial) ADjuVANt chemotherapy in the elderly: Developing and evaluating lower-toxicity chemotherapy options for older patients with breast cancer. J Geriatr Oncol. 2023 Jan; 14(1):101377.J Geriatr Oncol2022-09-23T00:00:002022'ADVANCE' (a pilot trial) ADjuVANt chemotherapy in the elderly: Developing and evaluating lower-toxicity chemotherapy options for older patients with breast cancer.35993306Trapani D, Ferraro E, Giugliano F, Boscolo Bielo L, Curigliano G, Burstein HJCurrent opinion in oncologyPostneoadjuvant treatment for triple-negative breast cancer. Curr Opin Oncol. 2022 11 01; 34(6):623-634.Curr Opin Oncol2022-08-19T00:00:002022Postneoadjuvant treatment for triple-negative breast cancer.Authorship 150749011Authorship 15071381Authorship 15069954536450763Sella T, Zheng Y, Tayob N, Ruddy KJ, Freedman RA, Dang C, Yardley D, Isakoff SJ, Valero V, DeMeo M, Burstein HJ, Winer EP, Wolff AC, Krop I, Partridge AH, Tolaney SMNPJ breast cancerTreatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT). NPJ Breast Cancer. 2022 Nov 30; 8(1):127.NPJ Breast Cancer2022-11-30T00:00:002022Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT).36435617Burstein HJHematology/oncology clinics of North AmericaEscalation, De-escalation, Adaptation, Speciation, Customization: The New Approaches to Breast Cancer. Hematol Oncol Clin North Am. 2023 02; 37(1):xiii-xvi.Hematol Oncol Clin North Am2023-02-01T00:00:002023Escalation, De-escalation, Adaptation, Speciation, Customization: The New Approaches to Breast Cancer.Authorship 15086901136493334Francis PA, Fleming GF, Láng I, Ciruelos EM, Bonnefoi HR, Bellet M, Bernardo A, Climent MA, Martino S, Bermejo B, Burstein HJ, Davidson NE, Geyer CE, Walley BA, Ingle JN, Coleman RE, Müller B, Le Du F, Loibl S, Winer EP, Ruepp B, Loi S, Colleoni M, Coates AS, Gelber RD, Goldhirsch A, Regan MMJournal of clinical oncology : official journal of the American Society of Clinical OncologyAdjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT. J Clin Oncol. 2023 03 01; 41(7):1370-1375.J Clin Oncol2022-12-09T00:00:002022Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT.Authorship 1511451836521078Pagani O, Walley BA, Fleming GF, Colleoni M, Láng I, Gomez HL, Tondini C, Burstein HJ, Goetz MP, Ciruelos EM, Stearns V, Bonnefoi HR, Martino S, Geyer CE, Chini C, Puglisi F, Spazzapan S, Ruhstaller T, Winer EP, Ruepp B, Loi S, Coates AS, Gelber RD, Goldhirsch A, Regan MM, Francis PAJournal of clinical oncology : official journal of the American Society of Clinical OncologyAdjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials. J Clin Oncol. 2023 03 01; 41(7):1376-1382.J Clin Oncol2022-12-15T00:00:002022Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials.Authorship 15281802836858723Tolaney SM, Tarantino P, Graham N, Tayob N, Parè L, Villacampa G, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Barroso-Sousa R, Villagrasa P, DeMeo M, DiLullo M, Zanudo JGT, Weiss J, Wagle N, Partridge AH, Waks AG, Hudis CA, Krop IE, Burstein HJ, Prat A, Winer EPThe Lancet. OncologyAdjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial. Lancet Oncol. 2023 03; 24(3):273-285.Lancet Oncol2023-03-01T00:00:002023Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial.Authorship 153420621Authorship 1534418336949066Grinshpun A, Tolaney SM, Burstein HJ, Jeselsohn R, Mayer ELNPJ breast cancerThe dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer. NPJ Breast Cancer. 2023 Mar 22; 9(1):15.NPJ Breast Cancer2023-03-22T00:00:002023The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer.36945501Parsons HA, Blewett T, Chu X, Sridhar S, Santos K, Xiong K, Abramson VG, Patel A, Cheng J, Brufsky A, Rhoades J, Force J, Liu R, Traina TA, Carey LA, Rimawi MF, Miller KD, Stearns V, Specht J, Falkson C, Burstein HJ, Wolff AC, Winer EP, Tayob N, Krop IE, Makrigiorgos GM, Golub TR, Mayer EL, Adalsteinsson VAmedRxiv : the preprint server for health sciencesCirculating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030. medRxiv. 2023 Mar 08.medRxiv2023-03-08T00:00:002023Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030.Authorship 15639271Authorship 15530778Authorship 15575959Authorship 156943414Authorship 15640942037269905Tarantino P, Viale G, Press MF, Hu X, Penault-Llorca F, Bardia A, Batistatou A, Burstein HJ, Carey LA, Cortes J, Denkert C, Diéras V, Jacot W, Koutras AK, Lebeau A, Loibl S, Modi S, Mosele MF, Provenzano E, Pruneri G, Reis-Filho JS, Rojo F, Salgado R, Schmid P, Schnitt SJ, Tolaney SM, Trapani D, Vincent-Salomon A, Wolff AC, Pentheroudakis G, André F, Curigliano GAnnals of oncology : official journal of the European Society for Medical OncologyESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer. Ann Oncol. 2023 08; 34(8):645-659.Ann Oncol2023-06-01T00:00:002023ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer.37042724Mayerhofer C, Sedrak MS, Hopkins JO, Li T, Tayob N, Faggen MG, Sinclair NF, Chen WY, Parsons HA, Mayer EL, Lange PB, Basta AS, Perilla-Glen A, Lederman RI, Wong AR, Tiwari A, McAllister SS, Mittendorf EA, Gibson CJ, Burstein HJ, Kim AS, Freedman RA, Miller PGJournal of the National Cancer InstituteClonal hematopoiesis in older patients with breast cancer receiving chemotherapy. J Natl Cancer Inst. 2023 08 08; 115(8):981-988.J Natl Cancer Inst2023-08-08T00:00:002023Clonal hematopoiesis in older patients with breast cancer receiving chemotherapy.37196213Burstein HJ, DeMichele A, Somerfield MR, Henry NLJournal of clinical oncology : official journal of the American Society of Clinical OncologyTesting for ESR1 Mutations to Guide Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update. J Clin Oncol. 2023 06 20; 41(18):3423-3425.J Clin Oncol2023-05-17T00:00:002023Testing for ESR1 Mutations to Guide Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update.37308117Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, Allison KH, Anderson B, Burstein HJ, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Hurvitz SA, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch AM, Lyons J, Mortimer J, Patel SA, Pierce LJ, Rosenberger LH, Rugo HS, Schneider B, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Wei M, Wisinski KB, Young JS, Yeung K, Dwyer MA, Kumar RJournal of the National Comprehensive Cancer Network : JNCCNNCCN Guidelines® Insights: Breast Cancer, Version 4.2023. J Natl Compr Canc Netw. 2023 06; 21(6):594-608.J Natl Compr Canc Netw2023-06-01T00:00:002023NCCN Guidelines® Insights: Breast Cancer, Version 4.2023.37192427Trapani D, Jin Q, Block CC, Freedman RA, Lin NU, Tarantino P, Mittendorf EA, King TA, Lester SC, Brock JE, Tayob N, Bunnell CA, Tolaney SM, Burstein HJJCO oncology practiceIdentifying Patterns and Barriers in OncotypeDX Recurrence Score Testing in Older Patients With Early-Stage, Estrogen Receptor-Positive Breast Cancer: Implications for Guidance and Reimbursement. JCO Oncol Pract. 2023 08; 19(8):560-570.JCO Oncol Pract2023-05-16T00:00:002023Identifying Patterns and Barriers in OncotypeDX Recurrence Score Testing in Older Patients With Early-Stage, Estrogen Receptor-Positive Breast Cancer: Implications for Guidance and Reimbursement.Authorship 34353111Authorship 3547861Authorship 158197321Authorship 15922392Authorship 15840951837597579Parsons HA, Blewett T, Chu X, Sridhar S, Santos K, Xiong K, Abramson VG, Patel A, Cheng J, Brufsky A, Rhoades J, Force J, Liu R, Traina TA, Carey LA, Rimawi MF, Miller KD, Stearns V, Specht J, Falkson C, Burstein HJ, Wolff AC, Winer EP, Tayob N, Krop IE, Makrigiorgos GM, Golub TR, Mayer EL, Adalsteinsson VAAnnals of oncology : official journal of the European Society for Medical OncologyCirculating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030. Ann Oncol. 2023 10; 34(10):899-906.Ann Oncol2023-08-18T00:00:002023Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030.37556775Pfeiler G, Hlauschek D, Mayer EL, Deutschmann C, Kacerovsky-Strobl S, Martin M, Meisel JL, Zdenkowski N, Loibl S, Balic M, Park H, Prat A, Isaacs C, Bajetta E, Balko JM, Bellet-Ezquerra M, Bliss J, Burstein H, Cardoso F, Fohler H, Foukakis T, Gelmon KA, Goetz M, Haddad TC, Iwata H, Jassem J, Lee SC, Linderholm B, Los M, Mamounas EP, Miller KD, Morris PG, Munzone E, Gal-Yam EN, Ring A, Shepherd L, Singer C, Thomssen C, Tseng LM, Valagussa P, Winer EP, Wolff AC, Zoppoli G, Machacek-Link J, Schurmans C, Huang X, Gauthier E, Fesl C, Dueck AC, DeMichele A, Gnant MJournal of clinical oncology : official journal of the American Society of Clinical OncologyImpact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial. J Clin Oncol. 2023 Nov 20; 41(33):5118-5130.J Clin Oncol2023-08-09T00:00:002023Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial.37683978Curigliano G, Burstein HJ, Gnant M, Loibl S, Cameron D, Regan MM, Denkert C, Poortmans P, Weber WP, Thürlimann BAnnals of oncology : official journal of the European Society for Medical OncologyUnderstanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023. Ann Oncol. 2023 11; 34(11):970-986.Ann Oncol2023-09-06T00:00:002023Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023.Authorship 4728374Authorship 16115371038019444Mayer EL, Tayob N, Ren S, Savoie JJ, Spigel DR, Burris HA, Ryan PD, Harris LN, Winer EP, Burstein HJBreast cancer research and treatmentA randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer. Breast Cancer Res Treat. 2024 Feb; 204(1):123-132.Breast Cancer Res Treat2023-11-29T00:00:002023A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer.true1Professor of Medicine, EmeritusProfessor of Medicine, EmeritusAuthorship 1613927638101773Loibl S, André F, Bachelot T, Barrios CH, Bergh J, Burstein HJ, Cardoso MJ, Carey LA, Dawood S, Del Mastro L, Denkert C, Fallenberg EM, Francis PA, Gamal-Eldin H, Gelmon K, Geyer CE, Gnant M, Guarneri V, Gupta S, Kim SB, Krug D, Martin M, Meattini I, Morrow M, Janni W, Paluch-Shimon S, Partridge A, Poortmans P, Pusztai L, Regan MM, Sparano J, Spanic T, Swain S, Tjulandin S, Toi M, Trapani D, Tutt A, Xu B, Curigliano G, Harbeck NAnnals of oncology : official journal of the European Society for Medical OncologyEarly breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024 Feb; 35(2):159-182.Ann Oncol2023-12-13T00:00:002023Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.true1Associate Professor of MedicineAssociate Professor of MedicineAuthorship 5234443Authorship 1617771638161200Higgins T, Kantor O, Harrison B, Giordano J, McGrath M, Burstein HJ, Schnitt SJ, Rahman T, Vora H, Garrido-Castro A, Tolaney SM, Meric-Bernstam F, King TA, Mittendorf EAAnnals of surgical oncologyDefining the Biology of Estrogen Receptor-Low-Positive Breast Cancer. Ann Surg Oncol. 2024 Apr; 31(4):2244-2252.Ann Surg Oncol2023-12-31T00:00:002023Defining the Biology of Estrogen Receptor-Low-Positive Breast Cancer.Authorship 5346562Authorship 5518883Authorship 1623431638265615Higgins T, Kantor O, Harrison B, Giordano J, McGrath M, Burstein HJ, Schnitt SJ, Rahman T, Vora H, Garrido-Castro A, Tolaney SM, Meric-Bernstam F, King TA, Mittendorf EAAnnals of surgical oncologyASO Visual Abstract: Defining the Biology of Estrogen Receptor-Low Positive Breast Cancer. Ann Surg Oncol. 2024 Apr; 31(4):2284-2285.Ann Surg Oncol2024-04-01T00:00:002024ASO Visual Abstract: Defining the Biology of Estrogen Receptor-Low Positive Breast Cancer.Authorship 1701352Authorship 21778852PME MSPE WriterPME MSPE Writer3Chair of Pathways Admissions Subcommittee 2Chair of Pathways Admissions Subcommittee 2true1Professor of MedicineProfessor of MedicineAuthorship 579243Authorship 2268766Authorship 2338742Authorship 2781206Authorship 3278641Authorship 3708742Authorship 3966341Authorship 4183563Authorship 2386761Authorship 4447131Authorship 2847402Authorship 3181356Authorship 32719810Authorship 4887334Authorship 65213312Authorship 6639991Authorship 6532791Authorship 6619767Authorship 6450581Authorship 6543311Authorship 6637215Authorship 650440823349386Bunnell CA, Gross AH, Weingart SN, Kalfin MJ, Partridge A, Lane S, Burstein HJ, Fine B, Hilton NA, Sullivan C, Hagemeister EE, Kelly AE, Colicchio L, Szabatura AH, Winer EP, Salisbury M, Mann SBMJ quality & safetyHigh performance teamwork training and systems redesign in outpatient oncology. BMJ Qual Saf. 2013 May; 22(5):405-13.BMJ Qual Saf2013-01-24T00:00:002013High performance teamwork training and systems redesign in outpatient oncology.23645007Lin NU, Seah DS, Gelman R, Desantis S, Mayer EL, Isakoff S, Dipiro P, Krop IE, Come SE, Weckstein D, Winer EP, Burstein HJBreast cancer research and treatmentA phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2013 Jun; 139(2):403-10.Breast Cancer Res Treat2013-05-05T00:00:002013A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer.23744861Burstein HJJournal of the National Comprehensive Cancer Network : JNCCNLou Gehrig, Angelina Jolie, and cancer genetics. J Natl Compr Canc Netw. 2013 Jun 01; 11(6):631-2.J Natl Compr Canc Netw2013-06-01T00:00:002013Lou Gehrig, Angelina Jolie, and cancer genetics.23946169Burstein HJJournal of the National Comprehensive Cancer Network : JNCCNLucky to be an oncologist. J Natl Compr Canc Netw. 2013 Aug; 11(8):909-10.J Natl Compr Canc Netw2013-08-01T00:00:002013Lucky to be an oncologist.23352568Olson EM, Najita JS, Sohl J, Arnaout A, Burstein HJ, Winer EP, Lin NUBreast (Edinburgh, Scotland)Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era. Breast. 2013 Aug; 22(4):525-31.Breast2013-01-23T00:00:002013Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era.23667200Burstein HJJournal of the National Comprehensive Cancer Network : JNCCNOff-label use of oncology drugs: too much, too little, or just right? J Natl Compr Canc Netw. 2013 May 01; 11(5):505-6.J Natl Compr Canc Netw2013-05-01T00:00:002013Off-label use of oncology drugs: too much, too little, or just right?23829891Vaz-Luis I, Seah D, Olson EM, Wagle N, Metzger-Filho O, Sohl J, Litsas G, Burstein HJ, Krop IE, Winer EP, Lin NUClinical breast cancerClinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study. Clin Breast Cancer. 2013 Aug; 13(4):254-63.Clin Breast Cancer2013-08-01T00:00:002013Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study.23915750Burstein HJHematology/oncology clinics of North AmericaBreast cancer treatment in the era of individualized care. Hematol Oncol Clin North Am. 2013 Aug; 27(4):xiii-xv.Hematol Oncol Clin North Am2013-06-10T00:00:002013Breast cancer treatment in the era of individualized care.Authorship 5146352Authorship 674987523847214Theriault RL, Carlson RW, Allred C, Anderson BO, Burstein HJ, Edge SB, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Schwartzberg LS, Smith ML, Soliman H, Somlo G, Ward JH, Wolff AC, Zellars R, Shead DA, Kumar RJournal of the National Comprehensive Cancer Network : JNCCNBreast cancer, version 3.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2013 Jul; 11(7):753-60; quiz 761.J Natl Compr Canc Netw2013-07-01T00:00:002013Breast cancer, version 3.2013: featured updates to the NCCN guidelines.Authorship 68143010Authorship 6811071Authorship 681030123906475Burstein HBreast (Edinburgh, Scotland)Expert opinion vs guideline based care: the St. Gallen Case study. Breast. 2013 Aug; 22 Suppl 2:S1-2.Breast2013-07-29T00:00:002013Expert opinion vs guideline based care: the St. Gallen Case study.24062210Ruddy KJ, Desantis SD, Gelman RS, Wu AH, Punglia RS, Mayer EL, Tolaney SM, Winer EP, Partridge AH, Burstein HJBreast cancer research and treatmentPersonalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice. Breast Cancer Res Treat. 2013 Oct; 141(3):421-7.Breast Cancer Res Treat2013-09-24T00:00:002013Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice.24074776Burstein HJBreast (Edinburgh, Scotland)Patients with triple negative breast cancer: is there an optimal adjuvant treatment? Breast. 2013 Aug; 22 Suppl 2:S147-8.Breast2013-08-01T00:00:002013Patients with triple negative breast cancer: is there an optimal adjuvant treatment?Authorship 28811Authorship 3172793Authorship 696004224262439Krop IE, Burstein HJJournal of the National Cancer InstituteTrastuzumab: qui bono? J Natl Cancer Inst. 2013 Dec 04; 105(23):1772-5.J Natl Cancer Inst2013-11-21T00:00:002013Trastuzumab: qui bono?Authorship 2245676Authorship 233091Authorship 704664824453294Seah DS, Luis IV, Macrae E, Sohl J, Litsas G, Winer EP, Lin NU, Burstein HJJournal of the National Comprehensive Cancer Network : JNCCNUse and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy. J Natl Compr Canc Netw. 2014 Jan; 12(1):71-80.J Natl Compr Canc Netw2014-01-01T00:00:002014Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy.Authorship 2627301Authorship 1946881Authorship 2642084Authorship 714279424717572Gradishar WJ, Anderson BO, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Marcom PK, Mayer IA, McCormick B, Miller RS, Pegram M, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith ML, Soliman H, Somlo G, Ward JH, Wolff AC, Zellars R, Shead DA, Kumar RJournal of the National Comprehensive Cancer Network : JNCCNBreast cancer version 3.2014. J Natl Compr Canc Netw. 2014 Apr; 12(4):542-90.J Natl Compr Canc Netw2014-04-01T00:00:002014Breast cancer version 3.2014.Authorship 897611Authorship 726380924663048Lyman GH, Temin S, Edge SB, Newman LA, Turner RR, Weaver DL, Benson AB, Bosserman LD, Burstein HJ, Cody H, Hayman J, Perkins CL, Podoloff DA, Giuliano AEJournal of clinical oncology : official journal of the American Society of Clinical OncologySentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2014 May 01; 32(13):1365-83.J Clin Oncol2014-03-24T00:00:002014Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update.Authorship 2258592Authorship 7319151Authorship 732280124855726Burstein HJOncology (Williston Park, N.Y.)Neoadjuvant pertuzumab: the exception that proves the rule? Oncology (Williston Park). 2014 Mar; 28(3):197-9.Oncology (Williston Park)2014-03-01T00:00:002014Neoadjuvant pertuzumab: the exception that proves the rule?24857085Burstein HJAmerican Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual MeetingFifty years of systemic therapy for breast cancer: from one size fits all to tailored therapy. Am Soc Clin Oncol Educ Book. 2014; e1-3.Am Soc Clin Oncol Educ Book2014-01-01T00:00:002014Fifty years of systemic therapy for breast cancer: from one size fits all to tailored therapy.Authorship 734382324451712Pritchard KI, Bergh J, Burstein HJAmerican Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual MeetingUpdate of the oxford overview: new insight and perspectives in the era of personalized medicine. Am Soc Clin Oncol Educ Book. 2012; 71-9.Am Soc Clin Oncol Educ Book2012-01-01T00:00:002012Update of the oxford overview: new insight and perspectives in the era of personalized medicine.Authorship 739344424888802Sledge GW, Mamounas EP, Hortobagyi GN, Burstein HJ, Goodwin PJ, Wolff ACJournal of clinical oncology : official journal of the American Society of Clinical OncologyPast, present, and future challenges in breast cancer treatment. J Clin Oncol. 2014 Jul 01; 32(19):1979-86.J Clin Oncol2014-06-02T00:00:002014Past, present, and future challenges in breast cancer treatment.Authorship 3400391Authorship 7435405Authorship 744655924881463Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Láng I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer CE, Pinotti G, Puglisi F, Crivellari D, Ruhstaller T, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Bernhard J, Luo W, Ribi K, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PAThe New England journal of medicineAdjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014 Jul 10; 371(2):107-18.N Engl J Med2014-06-01T00:00:002014Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.24888816Vaz-Luis I, Ottesen RA, Hughes ME, Mamet R, Burstein HJ, Edge SB, Gonzalez-Angulo AM, Moy B, Rugo HS, Theriault RL, Weeks JC, Winer EP, Lin NUJournal of clinical oncology : official journal of the American Society of Clinical OncologyOutcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. J Clin Oncol. 2014 Jul 10; 32(20):2142-50.J Clin Oncol2014-06-02T00:00:002014Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study.Authorship 4030171Authorship 3375444Authorship 273682Authorship 3104701Authorship 343821Authorship 4404272Authorship 74690111Authorship 745981124868023Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Rowden D, Solky AJ, Stearns V, Winer EP, Griggs JJJournal of clinical oncology : official journal of the American Society of Clinical OncologyAdjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. J Clin Oncol. 2014 Jul 20; 32(21):2255-69.J Clin Oncol2014-05-27T00:00:002014Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update.24934787Shulman LN, Berry DA, Cirrincione CT, Becker HP, Perez EA, O'Regan R, Martino S, Shapiro CL, Schneider CJ, Kimmick G, Burstein HJ, Norton L, Muss H, Hudis CA, Winer EPJournal of clinical oncology : official journal of the American Society of Clinical OncologyComparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). J Clin Oncol. 2014 Aug 01; 32(22):2311-7.J Clin Oncol2014-06-16T00:00:002014Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance).Authorship 3526903Authorship 810922Authorship 940063Authorship 968102Authorship 772182125348000Burstein HJ, Cirrincione CT, Barry WT, Chew HK, Tolaney SM, Lake DE, Ma C, Blackwell KL, Winer EP, Hudis CAJournal of clinical oncology : official journal of the American Society of Clinical OncologyEndocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer-CALGB 40302 (Alliance). J Clin Oncol. 2014 Dec 10; 32(35):3959-66.J Clin Oncol2014-10-27T00:00:002014Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer-CALGB 40302 (Alliance).Authorship 500901Authorship 5379182Authorship 77879118Authorship 7774701125205424Mayer EL, Gropper AB, Harris L, Gold JM, Parker L, Kuter I, Come S, Najita JS, Guo H, Winer EP, Burstein HJClinical breast cancerLong-term follow-up after preoperative trastuzumab and chemotherapy for HER2-overexpressing breast cancer. Clin Breast Cancer. 2015 Feb; 15(1):24-30.Clin Breast Cancer2014-08-15T00:00:002014Long-term follow-up after preoperative trastuzumab and chemotherapy for HER2-overexpressing breast cancer.25564897Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Guo H, Hudis CA, Krop IE, Burstein HJ, Winer EPThe New England journal of medicineAdjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med. 2015 Jan 08; 372(2):134-41.N Engl J Med2015-01-08T00:00:002015Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.Authorship 943431Authorship 5761525Authorship 751573Authorship 4225311Authorship 4460591Authorship 4896011Authorship 3585831Authorship 3602731Authorship 4581581Authorship 4662341Authorship 4757981Authorship 4882881Authorship 4972621Authorship 3728122Authorship 50591Authorship 4832169Authorship 1627801Authorship 1740594Authorship 5602944Authorship 5014399Authorship 2248732Authorship 5178303Authorship 523641Authorship 2842263Authorship 28674810Authorship 4448771Authorship 4552555Authorship 4747431Authorship 5634301Authorship 773037Authorship 2876238Authorship 2925532Authorship 1108991Authorship 3094111Authorship 3119893Authorship 2463673Authorship 3338021Authorship 2698331Authorship 2703072Authorship 2078991Authorship 2313191Authorship 2532924Authorship 2121873Authorship 4334791Authorship 33358810Authorship 3097905Authorship 4127008Authorship 3900311Authorship 5684954Authorship 3959391Authorship 3726911Authorship 4480931Authorship 4524621Authorship 1580331Authorship 4556377Authorship 4748361Authorship 5027631Authorship 5170431Authorship 5660641Authorship 5702273Authorship 7917075Authorship 8033615Authorship 80732410Authorship 7875692Authorship 7942351725495490Francis PA, Regan MM, Fleming GF, Láng I, Ciruelos E, Bellet M, Bonnefoi HR, Climent MA, Da Prada GA, Burstein HJ, Martino S, Davidson NE, Geyer CE, Walley BA, Coleman R, Kerbrat P, Buchholz S, Ingle JN, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Colleoni M, Viale G, Coates AS, Goldhirsch A, Gelber RDThe New England journal of medicineAdjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015 Jan 29; 372(5):436-46.N Engl J Med2014-12-11T00:00:002014Adjuvant ovarian suppression in premenopausal breast cancer.25605863Masters GA, Krilov L, Bailey HH, Brose MS, Burstein H, Diller LR, Dizon DS, Fine HA, Kalemkerian GP, Moasser M, Neuss MN, O'Day SJ, Odenike O, Ryan CJ, Schilsky RL, Schwartz GK, Venook AP, Wong SL, Patel JDJournal of clinical oncology : official journal of the American Society of Clinical OncologyClinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol. 2015 Mar 01; 33(7):786-809.J Clin Oncol2015-01-20T00:00:002015Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology.21738119Perez E, Burstein HJ, Hudis CClinical advances in hematology & oncology : H&ORecent advances in the treatment of breast cancer: highlights from the 2010 San Antonio Breast Cancer Symposium. Clin Adv Hematol Oncol. 2011 May; 9(5 Suppl 11):1-16.Clin Adv Hematol Oncol2011-05-01T00:00:002011Recent advances in the treatment of breast cancer: highlights from the 2010 San Antonio Breast Cancer Symposium.25981899Ruddy KJ, Guo H, Barry W, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Hudis C, Krop IE, Burstein HJ, Winer EP, Partridge AH, Tolaney SMBreast cancer research and treatmentChemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial). Breast Cancer Res Treat. 2015 Jun; 151(3):589-96.Breast Cancer Res Treat2015-05-16T00:00:002015Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial).25870381Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar RJournal of the National Comprehensive Cancer Network : JNCCNBreast Cancer Version 2.2015. J Natl Compr Canc Netw. 2015 Apr; 13(4):448-75.J Natl Compr Canc Netw2015-04-01T00:00:002015Breast Cancer Version 2.2015.Authorship 715381Authorship 2859541Authorship 3220442Authorship 2611041Authorship 2640331Authorship 2869661Authorship 5337961Authorship 3747161Authorship 3969101Authorship 4527251Authorship 813912526092816Bernhard J, Luo W, Ribi K, Colleoni M, Burstein HJ, Tondini C, Pinotti G, Spazzapan S, Ruhstaller T, Puglisi F, Pavesi L, Parmar V, Regan MM, Pagani O, Fleming GF, Francis PA, Price KN, Coates AS, Gelber RD, Goldhirsch A, Walley BAThe Lancet. OncologyPatient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. Lancet Oncol. 2015 Jul; 16(7):848-58.Lancet Oncol2015-06-16T00:00:002015Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.Authorship 8172804Authorship 817770126200984Burstein HJ, Morrow MThe New England journal of medicineNodal Irradiation after Breast-Cancer Surgery in the Era of Effective Adjuvant Therapy. N Engl J Med. 2015 Jul 23; 373(4):379-81.N Engl J Med2015-07-23T00:00:002015Nodal Irradiation after Breast-Cancer Surgery in the Era of Effective Adjuvant Therapy.25967907Reddy P, Blouin GC, Yeh YC, Burstein HJJournal of oncology practiceChoosing Treatments on the Basis of Cost: Can Clinicians Opt for Less Expensive Treatments? J Oncol Pract. 2015 Jul; 11(4):322-4.J Oncol Pract2015-05-12T00:00:002015Choosing Treatments on the Basis of Cost: Can Clinicians Opt for Less Expensive Treatments?Authorship 3685841Authorship 8187041Authorship 8197422Authorship 81987211310781Burstein H, Bizub D, Kotler M, Schatz G, Vogt VM, Skalka AMJournal of virologyProcessing of avian retroviral gag polyprotein precursors is blocked by a mutation at the NC-PR cleavage site. J Virol. 1992 Mar; 66(3):1781-5.J Virol1992-03-01T00:00:001992Processing of avian retroviral gag polyprotein precursors is blocked by a mutation at the NC-PR cleavage site.1322601Vogt VM, Burstein H, Skalka AMVirologyProteolysis in the maturation of avian retroviruses does not require calcium. Virology. 1992 Aug; 189(2):771-4.Virology1992-08-01T00:00:001992Proteolysis in the maturation of avian retroviruses does not require calcium.1656090Burstein H, Bizub D, Skalka AMJournal of virologyAssembly and processing of avian retroviral gag polyproteins containing linked protease dimers. J Virol. 1991 Nov; 65(11):6165-72.J Virol1991-11-01T00:00:001991Assembly and processing of avian retroviral gag polyproteins containing linked protease dimers.Authorship 4304031Authorship 4398201Authorship 4478451Authorship 8398712Authorship 840412226443566Vaz-Luis I, Burstein HJBMJ (Clinical research ed.)With better adjuvant therapy, does breast cancer stage still matter? BMJ. 2015 Oct 06; 351:h5273.BMJ2015-10-06T00:00:002015With better adjuvant therapy, does breast cancer stage still matter?26211823Mayer EL, Burstein HJLancet (London, England)Postmenopausal breast cancer: a best endocrine strategy? Lancet. 2015 Oct 03; 386(10001):1317-1319.Lancet2015-07-23T00:00:002015Postmenopausal breast cancer: a best endocrine strategy?Authorship 4380101Authorship 4482821Authorship 848915226279133Mayer EL, Burstein HJBreast (Edinburgh, Scotland)Adjuvant endocrine therapy for postmenopausal women: Type and duration. Breast. 2015 Nov; 24 Suppl 2:S126-8.Breast2015-08-14T00:00:002015Adjuvant endocrine therapy for postmenopausal women: Type and duration.Authorship 5351862Authorship 853426526656517Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar RJournal of the National Comprehensive Cancer Network : JNCCNNCCN Guidelines Insights Breast Cancer, Version 1.2016. J Natl Compr Canc Netw. 2015 Dec; 13(12):1475-85.J Natl Compr Canc Netw2015-12-01T00:00:002015NCCN Guidelines Insights Breast Cancer, Version 1.2016.Authorship 4397512Authorship 8607521726539793Dang C, Guo H, Najita J, Yardley D, Marcom K, Albain K, Rugo H, Miller K, Ellis M, Shapira I, Wolff AC, Carey LA, Moy B, Groarke J, Moslehi J, Krop I, Burstein HJ, Hudis C, Winer EP, Tolaney SMJAMA oncologyCardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. JAMA Oncol. 2016 Jan; 2(1):29-36.JAMA Oncol2016-01-01T00:00:002016Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.Authorship 868461526957618Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar RJournal of the National Comprehensive Cancer Network : JNCCNInvasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016 Mar; 14(3):324-54.J Natl Compr Canc Netw2016-03-01T00:00:002016Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.Authorship 32908922001-08-17T00:00:002001-06-25T00:00:00Defining the Health Care Needs for Breast Cancer Survivors
PASTEURSummerAuthorship 3774681Authorship 877004126931400Burstein HJ, Lacchetti C, Griggs JJJournal of oncology practiceAdjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression Summary. J Oncol Pract. 2016 Apr; 12(4):390-3.J Oncol Pract2016-03-01T00:00:002016Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression Summary.Authorship 8799275Authorship 8800381Authorship 879939227136229Ma AD, Burstein HJAnnals of internal medicineUpdate in Hematology and Oncology: Evidence Published in 2015. Ann Intern Med. 2016 May 03; 164(9):W32-6.Ann Intern Med2016-05-03T00:00:002016Update in Hematology and Oncology: Evidence Published in 2015.27022111Ribi K, Luo W, Bernhard J, Francis PA, Burstein HJ, Ciruelos E, Bellet M, Pavesi L, Lluch A, Visini M, Parmar V, Tondini C, Kerbrat P, Perelló A, Neven P, Torres R, Lombardi D, Puglisi F, Karlsson P, Ruhstaller T, Colleoni M, Coates AS, Goldhirsch A, Price KN, Gelber RD, Regan MM, Fleming GFJournal of clinical oncology : official journal of the American Society of Clinical OncologyAdjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial. J Clin Oncol. 2016 05 10; 34(14):1601-10.J Clin Oncol2016-03-28T00:00:002016Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial.26884586Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Solky AJ, Stearns V, Winer EP, Griggs JJJournal of clinical oncology : official journal of the American Society of Clinical OncologyAdjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression. J Clin Oncol. 2016 05 10; 34(14):1689-701.J Clin Oncol2016-02-16T00:00:002016Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression.Authorship 886630327221996Rugo HS, Rumble RB, Burstein HJJournal of oncology practiceEndocrine Therapy for Hormone Receptor Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline Summary. J Oncol Pract. 2016 Jun; 12(6):583-7.J Oncol Pract2016-05-24T00:00:002016Endocrine Therapy for Hormone Receptor Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline Summary.2Assistant Professor1Associate Professor0Full Professor5Other FacultyAuthorship 5762966Authorship 75191Authorship 4921481Authorship 5390921Authorship 4815253Authorship 9082601627217461Rugo HS, Rumble RB, Macrae E, Barton DL, Connolly HK, Dickler MN, Fallowfield L, Fowble B, Ingle JN, Jahanzeb M, Johnston SR, Korde LA, Khatcheressian JL, Mehta RS, Muss HB, Burstein HJJournal of clinical oncology : official journal of the American Society of Clinical OncologyEndocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline. J Clin Oncol. 2016 09 01; 34(25):3069-103.J Clin Oncol2016-05-23T00:00:002016Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline.2015-03-31BURSTEIN, HAROLD J.1982-04-01Cancer and Leukemia Group BU10CA0322912019-02-28BURSTEIN, HAROLD JOHN2014-05-19NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer CareU10CA180867Principal InvestigatorPrincipal InvestigatorAuthorship 911593627484879Vaz-Luis I, Lin NU, Keating NL, Barry WT, Lii J, Burstein HJ, Winer EP, Freedman RABreast cancer research and treatmentTreatment of early-stage human epidermal growth factor 2-positive cancers among medicare enrollees: age and race strongly associated with non-use of trastuzumab. Breast Cancer Res Treat. 2016 08; 159(1):151-62.Breast Cancer Res Treat2016-08-02T00:00:002016Treatment of early-stage human epidermal growth factor 2-positive cancers among medicare enrollees: age and race strongly associated with non-use of trastuzumab.Authorship 916331227551109Mayer EL, Burstein HJJournal of clinical oncology : official journal of the American Society of Clinical OncologyChemotherapy for Triple-Negative Breast Cancer: Is More Better? J Clin Oncol. 2016 10 01; 34(28):3369-71.J Clin Oncol2016-08-22T00:00:002016Chemotherapy for Triple-Negative Breast Cancer: Is More Better?Authorship 607498Authorship 9270241027704226Golshan M, Cirrincione CT, Sikov WM, Carey LA, Berry DA, Overmoyer B, Henry NL, Somlo G, Port E, Burstein HJ, Hudis C, Winer E, Ollila DWBreast cancer research and treatmentImpact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance). Breast Cancer Res Treat. 2016 11; 160(2):297-304.Breast Cancer Res Treat2016-10-04T00:00:002016Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance).Authorship 4374581Authorship 4433461Authorship 4732754Authorship 4873556Authorship 5363701Authorship 9329653Authorship 937143227825710Criscitiello C, Curigliano G, Burstein HJ, Wong S, Esposito A, Viale G, Giuliano M, Veronesi U, Santangelo M, Golshan MEuropean journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical OncologyBreast conservation following neoadjuvant therapy for breast cancer in the modern era: Are we losing the opportunity? Eur J Surg Oncol. 2016 Dec; 42(12):1780-1786.Eur J Surg Oncol2016-10-29T00:00:002016Breast conservation following neoadjuvant therapy for breast cancer in the modern era: Are we losing the opportunity?27631400Vaz-Luis I, Burstein HJJAMA oncologyOptimizing Adjuvant Chemotherapy and Surgery for Early- and Late-Stage Breast Cancer. JAMA Oncol. 2016 Nov 01; 2(11):1399-1400.JAMA Oncol2016-11-01T00:00:002016Optimizing Adjuvant Chemotherapy and Surgery for Early- and Late-Stage Breast Cancer.Authorship 3005881Authorship 9408671Authorship 9438873Authorship 9423909Authorship 94409310Authorship 942043927953751Deprimo SE, Friece C, Huang X, Smeraglia J, Sherman L, Collier M, Baum C, Elias AD, Burstein HJ, Miller KDJournal of clinical oncology : official journal of the American Society of Clinical OncologyEffect of treatment with sunitinib malate, a multitargeted tyrosine kinase inhibitor, on circulating plasma levels of VEGF, soluble VEGF receptors 2 and 3, and soluble KIT in patients with metastatic breast cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):578.J Clin Oncol2006-06-20T00:00:002006Effect of treatment with sunitinib malate, a multitargeted tyrosine kinase inhibitor, on circulating plasma levels of VEGF, soluble VEGF receptors 2 and 3, and soluble KIT in patients with metastatic breast cancer.27954839Peppercorn J, Joffe S, Burstein HJ, Winer EJournal of clinical oncology : official journal of the American Society of Clinical OncologyUse of experimental therapy outside of clinical trials among U.S. oncologists. J Clin Oncol. 2006 Jun 20; 24(18_suppl):6047.J Clin Oncol2006-06-20T00:00:002006Use of experimental therapy outside of clinical trials among U.S. oncologists.27952013Mayer EL, Harris LN, Partridge AH, Gelman RS, Schumer ST, Comanaru RS, Long M, Sampson E, Burstein HJ, Winer EPJournal of clinical oncology : official journal of the American Society of Clinical OncologyCombination therapy with gefitinib and capecitabine in metastatic breast cancer (MBC): A phase I trial. J Clin Oncol. 2006 Jun 20; 24(18_suppl):10564.J Clin Oncol2006-06-20T00:00:002006Combination therapy with gefitinib and capecitabine in metastatic breast cancer (MBC): A phase I trial.27952232Burstein HJ, Keshaviah A, Baron A, Hart R, Lambert-Falls R, Marcom PK, Gelman R, Winer EPJournal of clinical oncology : official journal of the American Society of Clinical OncologyTrastuzumab and vinorelbine or taxane chemotherapy for HER2+ metastatic breast cancer: The TRAVIOTA study. J Clin Oncol. 2006 Jun 20; 24(18_suppl):650.J Clin Oncol2006-06-20T00:00:002006Trastuzumab and vinorelbine or taxane chemotherapy for HER2+ metastatic breast cancer: The TRAVIOTA study.27960736Gold JM, Najita JS, Lester S, Richardson AL, Morganstern DE, Chen WY, Partridge AH, Krop IE, Winer EP, Burstein HJJournal of clinical oncology : official journal of the American Society of Clinical OncologyPersonalizing treatment in early-stage breast cancer: The role of standard clinical factors and genomic information in adjuvant chemotherapy decision making. J Clin Oncol. 2009 May 20; 27(15_suppl):572.J Clin Oncol2009-05-20T00:00:002009Personalizing treatment in early-stage breast cancer: The role of standard clinical factors and genomic information in adjuvant chemotherapy decision making.Authorship 9450177Authorship 9444921Authorship 9444431Authorship 9459202Authorship 9457052Authorship 9457196Authorship 9459576Authorship 94598181315756Grinde B, Cameron CE, Leis J, Weber IT, Wlodawer A, Burstein H, Skalka AMThe Journal of biological chemistryAnalysis of substrate interactions of the Rous sarcoma virus wild type and mutant proteases and human immunodeficiency virus-1 protease using a set of systematically altered peptide substrates. J Biol Chem. 1992 May 15; 267(14):9491-8.J Biol Chem1992-05-15T00:00:001992Analysis of substrate interactions of the Rous sarcoma virus wild type and mutant proteases and human immunodeficiency virus-1 protease using a set of systematically altered peptide substrates.28023110Gropper A, Burstein HJ, Harris L, Anderson KS, Gold JM, Younger WJ, Bunnell CA, Najita JS, Winer EP, Mayer ELJournal of clinical oncology : official journal of the American Society of Clinical OncologyLong-term outcomes after neoadjuvant trastuzumab and chemotherapy for HER2+ breast cancer. J Clin Oncol. 2011 May 20; 29(15_suppl):e11074.J Clin Oncol2011-05-20T00:00:002011Long-term outcomes after neoadjuvant trastuzumab and chemotherapy for HER2+ breast cancer.1315755Grinde B, Cameron CE, Leis J, Weber IT, Wlodawer A, Burstein H, Bizub D, Skalka AMThe Journal of biological chemistryMutations that alter the activity of the Rous sarcoma virus protease. J Biol Chem. 1992 May 15; 267(14):9481-90.J Biol Chem1992-05-15T00:00:001992Mutations that alter the activity of the Rous sarcoma virus protease.28016595Baselga J, Fumoleau P, Gil M, Colomer R, Roche H, Cortes-Funes H, Burstein H, Kaufman P, Kong S, Moore LJournal of clinical oncology : official journal of the American Society of Clinical OncologyPhase II, 3-arm study of CCI-779 in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer: preliminary results. J Clin Oncol. 2004 Jul 15; 22(14_suppl):544.J Clin Oncol2004-07-15T00:00:002004Phase II, 3-arm study of CCI-779 in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer: preliminary results.8157644Cameron CE, Ridky TW, Shulenin S, Leis J, Weber IT, Copeland T, Wlodawer A, Burstein H, Bizub-Bender D, Skalka AMThe Journal of biological chemistryMutational analysis of the substrate binding pockets of the Rous sarcoma virus and human immunodeficiency virus-1 proteases. J Biol Chem. 1994 Apr 15; 269(15):11170-7.J Biol Chem1994-04-15T00:00:001994Mutational analysis of the substrate binding pockets of the Rous sarcoma virus and human immunodeficiency virus-1 proteases.8540349Cameron CE, Burstein H, Bizub-Bender D, Ridky T, Weber IT, Wlodawer A, Skalka AM, Leis JAdvances in experimental medicine and biologyIdentification of amino acid residues of the retroviral aspartic proteinases important for substrate specificity and catalytic efficiency. Adv Exp Med Biol. 1995; 362:399-406.Adv Exp Med Biol1995-01-01T00:00:001995Identification of amino acid residues of the retroviral aspartic proteinases important for substrate specificity and catalytic efficiency.28016577Burstein HJ, Overmoyer B, Gelman R, Silverman P, Savoie J, Clarke K, Dumadag L, Younger J, Winer EPJournal of clinical oncology : official journal of the American Society of Clinical OncologyRebeccamycin analog for refractory breast cancer: a randomized phase II trial. J Clin Oncol. 2004 Jul 15; 22(14_suppl):547.J Clin Oncol2004-07-15T00:00:002004Rebeccamycin analog for refractory breast cancer: a randomized phase II trial.27918782Burstein HJ, Schrag DJAMABiosimilar Therapy for ERBB2 (HER2)-Positive Breast Cancer: Close Enough? JAMA. 2017 01 03; 317(1):30-32.JAMA2017-01-03T00:00:002017Biosimilar Therapy for ERBB2 (HER2)-Positive Breast Cancer: Close Enough?Authorship 4437761Authorship 947364728040884Braun IM, Meyer FL, Gagne JJ, Nabati L, Yuppa DP, Carmona MA, Burstein HJ, Suzuki J, Nayak MM, Martins YPsycho-oncologyExperts' perspectives on the role of medical marijuana in oncology: A semistructured interview study. Psychooncology. 2017 08; 26(8):1087-1092.Psychooncology2017-01-26T00:00:002017Experts' perspectives on the role of medical marijuana in oncology: A semistructured interview study.Authorship 5334981Authorship 9558428Authorship 954414528147036Gross A, Kalfin M, Partridge AH, Lane S, Burstein HJ, Fine B, Hilton N, Sullivan C, Colicchio L, Hagemeister E, Kelly A, Szabatura A, Winer EP, Mann S, Weingart SJournal of clinical oncology : official journal of the American Society of Clinical OncologyImplementation of team training in outpatient breast oncology. J Clin Oncol. 2012 Dec; 30(34_suppl):83.J Clin Oncol2012-12-01T00:00:002012Implementation of team training in outpatient breast oncology.28141980Regan MM, Walley B, Fleming GF, Colleoni M, Lang I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer CE, Rabaglio-Poretti M, Coates AS, Gelber RD, Goldhirsch A, Francis PAJournal of clinical oncology : official journal of the American Society of Clinical OncologyRandomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Joint analysis of IBCSG TEXT and SOFT trials. J Clin Oncol. 2014 Jun 20; 32(18_suppl):LBA1.J Clin Oncol2014-06-20T00:00:002014Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Joint analysis of IBCSG TEXT and SOFT trials.10653885Burstein HJJournal of clinical oncology : official journal of the American Society of Clinical OncologySide effects of chemotherapy. Case 1. Radiation recall dermatitis from gemcitabine. J Clin Oncol. 2000 Feb; 18(3):693-4.J Clin Oncol2000-02-01T00:00:002000Side effects of chemotherapy. Case 1. Radiation recall dermatitis from gemcitabine.1684783Abbas AK, Williams ME, Burstein HJ, Chang TL, Bossu P, Lichtman AHImmunological reviewsActivation and functions of CD4+ T-cell subsets. Immunol Rev. 1991 Oct; 123:5-22.Immunol Rev1991-10-01T00:00:001991Activation and functions of CD4+ T-cell subsets.15289488Schrag D, Garewal HS, Burstein HJ, Samson DJ, Von Hoff DD, Somerfield MRJournal of clinical oncology : official journal of the American Society of Clinical OncologyAmerican Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol. 2004 Sep 01; 22(17):3631-8.J Clin Oncol2004-08-02T00:00:002004American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays.15545664Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MRJournal of clinical oncology : official journal of the American Society of Clinical OncologyAmerican Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol. 2005 Jan 20; 23(3):619-29.J Clin Oncol2004-11-15T00:00:002004American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.16293865Burstein HJ, Parker LM, Keshaviah A, Doherty J, Partridge AH, Schapira L, Ryan PD, Younger J, Harris LN, Moy B, Come SE, Schumer ST, Bunnell CA, Haldoupis M, Gelman R, Winer EPJournal of clinical oncology : official journal of the American Society of Clinical OncologyEfficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol. 2005 Nov 20; 23(33):8340-7.J Clin Oncol2005-11-20T00:00:002005Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy.16703595Punglia RS, Kuntz KM, Winer EP, Weeks JC, Burstein HJCancerThe impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis. Cancer. 2006 Jun 15; 106(12):2576-82.Cancer2006-06-15T00:00:002006The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis.11331338Burstein HJ, Swanson SJ, Christian RL, McMenamin MEJournal of clinical oncology : official journal of the American Society of Clinical OncologyUnusual aspects of breast cancer: case 2. Synchronous bilateral lung and breast cancers. J Clin Oncol. 2001 May 01; 19(9):2571-3.J Clin Oncol2001-05-01T00:00:002001Unusual aspects of breast cancer: case 2. Synchronous bilateral lung and breast cancers.11773307Partridge AH, Burstein HJ, Winer EPJournal of the National Cancer Institute. MonographsSide effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer. J Natl Cancer Inst Monogr. 2001; (30):135-42.J Natl Cancer Inst Monogr2001-01-01T00:00:002001Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer.Authorship 9603333Authorship 9658869Authorship 9663251Authorship 9649851Authorship 9651313Authorship 965916227949350Abel GA, Hevelone ND, Burstein HJ, Weeks JCJournal of clinical oncology : official journal of the American Society of Clinical OncologyCancer-related direct-to-consumer advertising: awareness, perceived impact, and associated patient and provider behavior. J Clin Oncol. 2008 May 20; 26(15_suppl):6631.J Clin Oncol2008-05-20T00:00:002008Cancer-related direct-to-consumer advertising: awareness, perceived impact, and associated patient and provider behavior.27951344O'Shaughnessy J, Blackwell KL, Burstein H, Storniolo AM, Sledge G, Baselga J, Koehler M, Laabs S, Florance A, Roychowdhury DJournal of clinical oncology : official journal of the American Society of Clinical OncologyA randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. J Clin Oncol. 2008 May 20; 26(15_suppl):1015.J Clin Oncol2008-05-20T00:00:002008A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy.27948554Mayer EL, Miller KD, Rugo HS, Peppercorn JM, Carey LA, Ryabin N, Josephs K, Winer EP, Burstein HJJournal of clinical oncology : official journal of the American Society of Clinical OncologyA pilot study of adjuvant bevacizumab and chemotherapy after neoadjuvant chemotherapy for high-risk breast cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):519.J Clin Oncol2008-05-20T00:00:002008A pilot study of adjuvant bevacizumab and chemotherapy after neoadjuvant chemotherapy for high-risk breast cancer.28148207Burstein HJ, Krilov L, Aragon-Ching JB, Baxter NN, Chiorean EG, Chow WA, De Groot JF, Devine SM, DuBois SG, El-Deiry WS, Epstein AS, Heymach J, Jones JA, Mayer DK, Miksad RA, Pennell NA, Sabel MS, Schilsky RL, Schuchter LM, Tung N, Winkfield KM, Wirth LJ, Dizon DSJournal of clinical oncology : official journal of the American Society of Clinical OncologyClinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2017 04 20; 35(12):1341-1367.J Clin Oncol2017-02-01T00:00:002017Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.27946470Miller KD, Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Pegram MD, Eisenberg PD, Collier M, Adams BJ, Baum CMJournal of clinical oncology : official journal of the American Society of Clinical OncologyPhase II study of SU11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC). J Clin Oncol. 2005 Jun; 23(16_suppl):563.J Clin Oncol2005-06-01T00:00:002005Phase II study of SU11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC).27946407Burstein HJ, Winer EP, Kuntz KM, Weeks JC, Punglia RSJournal of clinical oncology : official journal of the American Society of Clinical OncologyOptimizing endocrine therapy in postmenopausal women with early stage breast cancer: A decision analysis for biological subsets of tumors. J Clin Oncol. 2005 Jun; 23(16_suppl):529.J Clin Oncol2005-06-01T00:00:002005Optimizing endocrine therapy in postmenopausal women with early stage breast cancer: A decision analysis for biological subsets of tumors.18597715Carlson RW, Moench S, Hurria A, Balducci L, Burstein HJ, Goldstein LJ, Gradishar WJ, Hughes KS, Jahanzeb M, Lichtman SM, Marks LB, McClure JS, McCormick B, Nabell LM, Pierce LJ, Smith ML, Topham NS, Traina TA, Ward JH, Winer EPJournal of the National Comprehensive Cancer Network : JNCCNNCCN Task Force Report: breast cancer in the older woman. J Natl Compr Canc Netw. 2008; 6 Suppl 4:S1-25; quiz S26-7.J Natl Compr Canc Netw2008-01-01T00:00:002008NCCN Task Force Report: breast cancer in the older woman.19029413Peppercorn J, Burstein H, Miller FG, Winer E, Joffe SJournal of clinical oncology : official journal of the American Society of Clinical OncologySelf-reported practices and attitudes of US oncologists regarding off-protocol therapy. J Clin Oncol. 2008 Dec 20; 26(36):5994-6000.J Clin Oncol2008-11-24T00:00:002008Self-reported practices and attitudes of US oncologists regarding off-protocol therapy.12697865Earle CC, Burstein HJ, Winer EP, Weeks JCJournal of clinical oncology : official journal of the American Society of Clinical OncologyQuality of non-breast cancer health maintenance among elderly breast cancer survivors. J Clin Oncol. 2003 Apr 15; 21(8):1447-51.J Clin Oncol2003-04-15T00:00:002003Quality of non-breast cancer health maintenance among elderly breast cancer survivors.11934346Burstein HJ, Partridge AH, Lesnikoski BAExpert opinion on pharmacotherapyTreatment of breast cancer during pregnancy. Expert Opin Pharmacother. 2002 Apr; 3(4):423-8.Expert Opin Pharmacother2002-04-01T00:00:002002Treatment of breast cancer during pregnancy.12023144Jeter MD, Jänne PA, Brooks S, Burstein HJ, Wen P, Fuchs CS, Loeffler JS, Devlin PM, Salgia RInternational journal of radiation oncology, biology, physicsGemcitabine-induced radiation recall. Int J Radiat Oncol Biol Phys. 2002 Jun 01; 53(2):394-400.Int J Radiat Oncol Biol Phys2002-06-01T00:00:002002Gemcitabine-induced radiation recall.16157938Lyman GH, Giuliano AE, Somerfield MR, Benson AB, Bodurka DC, Burstein HJ, Cochran AJ, Cody HS, Edge SB, Galper S, Hayman JA, Kim TY, Perkins CL, Podoloff DA, Sivasubramaniam VH, Turner RR, Wahl R, Weaver DL, Wolff AC, Winer EPJournal of clinical oncology : official journal of the American Society of Clinical OncologyAmerican Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005 Oct 20; 23(30):7703-20.J Clin Oncol2005-09-12T00:00:002005American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer.16288876Peppercorn J, Partridge A, Burstein HJ, Winer EPBreast (Edinburgh, Scotland)Standards for follow-up care of patents with breast cancer. Breast. 2005 Dec; 14(6):500-8.Breast2005-12-01T00:00:002005Standards for follow-up care of patents with breast cancer.16813731Carlson RW, Moench SJ, Hammond ME, Perez EA, Burstein HJ, Allred DC, Vogel CL, Goldstein LJ, Somlo G, Gradishar WJ, Hudis CA, Jahanzeb M, Stark A, Wolff AC, Press MF, Winer EP, Paik S, Ljung BMJournal of the National Comprehensive Cancer Network : JNCCNHER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw. 2006 Jul; 4 Suppl 3:S1-22; quiz S23-4.J Natl Compr Canc Netw2006-07-01T00:00:002006HER2 testing in breast cancer: NCCN Task Force report and recommendations.Authorship 977078528404755Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Lyons J, Marcom PK, Mayer IA, McCormick B, Moran MS, O'Regan RM, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Sitapati A, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar RJournal of the National Comprehensive Cancer Network : JNCCNNCCN Guidelines Insights: Breast Cancer, Version 1.2017. J Natl Compr Canc Netw. 2017 04; 15(4):433-451.J Natl Compr Canc Netw2017-04-01T00:00:002017NCCN Guidelines Insights: Breast Cancer, Version 1.2017.17550053Burstein HJThe journal of supportive oncologyAnemia in cancer: update on studies of erythropoiesis-stimulating agents. J Support Oncol. 2007 Apr; 5(4 Suppl 2):5-26.J Support Oncol2007-04-01T00:00:002007Anemia in cancer: update on studies of erythropoiesis-stimulating agents.1534821Burstein HJ, Shea CM, Abbas AKJournal of immunology (Baltimore, Md. : 1950)Aqueous antigens induce in vivo tolerance selectively in IL-2- and IFN-gamma-producing (Th1) cells. J Immunol. 1992 Jun 15; 148(12):3687-91.J Immunol1992-06-15T00:00:001992Aqueous antigens induce in vivo tolerance selectively in IL-2- and IFN-gamma-producing (Th1) cells.11694788Winer EP, Burstein HJOncologyNew combinations with Herceptin in metastatic breast cancer. Oncology. 2001; 61 Suppl 2:50-7.Oncology2001-01-01T00:00:002001New combinations with Herceptin in metastatic breast cancer.21406472Wu Y, Amonkar MM, Sherrill BH, O'Shaughnessy J, Ellis C, Baselga J, Blackwell KL, Burstein HJAnnals of oncology : official journal of the European Society for Medical OncologyImpact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer. Ann Oncol. 2011 Dec; 22(12):2582-2590.Ann Oncol2011-03-15T00:00:002011Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer.21720992Punglia RS, Burstein HJ, Weeks JCCancerRadiation therapy for ductal carcinoma in situ: a decision analysis. Cancer. 2012 Feb 01; 118(3):603-11.Cancer2011-06-30T00:00:002011Radiation therapy for ductal carcinoma in situ: a decision analysis.21788567Burstein HJ, Mangu PB, Somerfield MR, Schrag D, Samson D, Holt L, Zelman D, Ajani JAJournal of clinical oncology : official journal of the American Society of Clinical OncologyAmerican Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays. J Clin Oncol. 2011 Aug 20; 29(24):3328-30.J Clin Oncol2011-07-25T00:00:002011American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays.22015280Burstein HJBreast (Edinburgh, Scotland)Patients with anti-HER2 responsive disease: definition and adjuvant therapies. Breast. 2011 Oct; 20 Suppl 3:S132-4.Breast2011-10-01T00:00:002011Patients with anti-HER2 responsive disease: definition and adjuvant therapies.22689807Blackwell KL, Burstein HJ, Storniolo AM, Rugo HS, Sledge G, Aktan G, Ellis C, Florance A, Vukelja S, Bischoff J, Baselga J, O'Shaughnessy JJournal of clinical oncology : official journal of the American Society of Clinical OncologyOverall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol. 2012 Jul 20; 30(21):2585-92.J Clin Oncol2012-06-11T00:00:002012Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.1716914Burstein HJ, Abbas AKCurrent opinion in immunologyT-cell-mediated activation of B cells. Curr Opin Immunol. 1991 Jun; 3(3):345-9.Curr Opin Immunol1991-06-01T00:00:001991T-cell-mediated activation of B cells.1919000Burstein HJ, Tepper RI, Leder P, Abbas AKJournal of immunology (Baltimore, Md. : 1950)Humoral immune functions in IL-4 transgenic mice. J Immunol. 1991 Nov 01; 147(9):2950-6.J Immunol1991-11-01T00:00:001991Humoral immune functions in IL-4 transgenic mice.11352965Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM, Manola J, Younger J, Matulonis U, Bunnell CA, Partridge AH, Richardson PG, Clarke K, Shulman LN, Winer EPJournal of clinical oncology : official journal of the American Society of Clinical OncologyClinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2001 May 15; 19(10):2722-30.J Clin Oncol2001-05-15T00:00:002001Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer.19404916Nunes RA, Li X, Kang SP, Burstein H, Roberts L, Carney W, Blackwell K, Ryan P, Borges V, Iglehart JD, Friedman P, Harris LNThe International journal of biological markersCirculating tumor cells in HER-2 positive metastatic breast cancer patients treated with trastuzumab and chemotherapy. Int J Biol Markers. 2009 Jan-Mar; 24(1):1-10.Int J Biol Markers2009-01-01T00:00:002009Circulating tumor cells in HER-2 positive metastatic breast cancer patients treated with trastuzumab and chemotherapy.19914532Burstein HJBreast (Edinburgh, Scotland)Late effects of adjuvant systemic therapies in women diagnosed with breast cancer at a young age. Breast. 2009 Oct; 18 Suppl 3:S135-6.Breast2009-10-01T00:00:002009Late effects of adjuvant systemic therapies in women diagnosed with breast cancer at a young age.20497961Mayer EL, Dhakil S, Patel T, Sundaram S, Fabian C, Kozloff M, Qamar R, Volterra F, Parmar H, Samant M, Burstein HJAnnals of oncology : official journal of the European Society for Medical OncologySABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer. Ann Oncol. 2010 Dec; 21(12):2370-2376.Ann Oncol2010-05-23T00:00:002010SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer.21482957Mayer EL, Dallabrida SM, Rupnick MA, Redline WM, Hannagan K, Ismail NS, Burstein HJ, Beckman JAHypertension (Dallas, Tex. : 1979)Contrary effects of the receptor tyrosine kinase inhibitor vandetanib on constitutive and flow-stimulated nitric oxide elaboration in humans. Hypertension. 2011 Jul; 58(1):85-92.Hypertension2011-04-11T00:00:002011Contrary effects of the receptor tyrosine kinase inhibitor vandetanib on constitutive and flow-stimulated nitric oxide elaboration in humans.15998905Punglia RS, Kuntz KM, Winer EP, Weeks JC, Burstein HJJournal of clinical oncology : official journal of the American Society of Clinical OncologyOptimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis. J Clin Oncol. 2005 Aug 01; 23(22):5178-87.J Clin Oncol2005-07-05T00:00:002005Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis.16243442Burstein HJ, Bellon JR, Galper S, Lu HM, Kuter I, Taghian AG, Wong J, Gelman R, Bunnell CA, Parker LM, Garber JE, Winer EP, Harris JR, Powell SNInternational journal of radiation oncology, biology, physicsProspective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer. Int J Radiat Oncol Biol Phys. 2006 Feb 01; 64(2):496-504.Int J Radiat Oncol Biol Phys2005-10-21T00:00:002005Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer.17888189Mayer EL, Carey LA, Burstein HJBreast cancer research : BCRClinical trial update: implications and management of residual disease after neoadjuvant therapy for breast cancer. Breast Cancer Res. 2007; 9(5):110.Breast Cancer Res2007-01-01T00:00:002007Clinical trial update: implications and management of residual disease after neoadjuvant therapy for breast cancer.18258991Gralow JR, Burstein HJ, Wood W, Hortobagyi GN, Gianni L, von Minckwitz G, Buzdar AU, Smith IE, Symmans WF, Singh B, Winer EPJournal of clinical oncology : official journal of the American Society of Clinical OncologyPreoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol. 2008 Feb 10; 26(5):814-9.J Clin Oncol2008-02-10T00:00:002008Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease.Authorship 987659328580881Wander SA, Mayer EL, Burstein HJJournal of clinical oncology : official journal of the American Society of Clinical OncologyBlocking the Cycle: Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic, Hormone Receptor-Positive Breast Cancer. J Clin Oncol. 2017 Sep 01; 35(25):2866-2870.J Clin Oncol2017-06-03T00:00:002017Blocking the Cycle: Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic, Hormone Receptor-Positive Breast Cancer.19186396Burstein HJJournal of the National Comprehensive Cancer Network : JNCCNConflict of interest and oncology guidelines. J Natl Compr Canc Netw. 2008 Nov; 6(10):955.J Natl Compr Canc Netw2008-11-01T00:00:002008Conflict of interest and oncology guidelines.14663782Partridge AH, Winer EP, Burstein HJSeminars in oncologyFollow-up care of breast cancer survivors. Semin Oncol. 2003 Dec; 30(6):817-25.Semin Oncol2003-12-01T00:00:002003Follow-up care of breast cancer survivors.17370924Burstein HJOncology (Williston Park, N.Y.)Myeloid growth factor support for dose-dense adjuvant chemotherapy for breast cancer. Oncology (Williston Park). 2006 Dec; 20(14 Suppl 9):13-5.Oncology (Williston Park)2006-12-01T00:00:002006Myeloid growth factor support for dose-dense adjuvant chemotherapy for breast cancer.18375893Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, Gipson G, Burstein H, Lake D, Shapiro CL, Ungaro P, Norton L, Winer E, Hudis CJournal of clinical oncology : official journal of the American Society of Clinical OncologyRandomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol. 2008 Apr 01; 26(10):1642-9.J Clin Oncol2008-04-01T00:00:002008Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.19406038Burstein HJJournal of the National Comprehensive Cancer Network : JNCCNSPIKES for difficult conversations with cancer patients. J Natl Compr Canc Netw. 2009 Apr; 7(4):341.J Natl Compr Canc Netw2009-04-01T00:00:002009SPIKES for difficult conversations with cancer patients.18445827Punglia RS, Burstein HJ, Winer EP, Weeks JCJournal of the National Cancer InstitutePharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. J Natl Cancer Inst. 2008 May 07; 100(9):642-8.J Natl Cancer Inst2008-04-29T00:00:002008Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.22411347Burstein HJNature reviews. Clinical oncologyBreast cancer: Neoadjuvant bevacizumab treatment-signal or noise? Nat Rev Clin Oncol. 2012 Mar 13; 9(4):191-2.Nat Rev Clin Oncol2012-03-13T00:00:002012Breast cancer: Neoadjuvant bevacizumab treatment-signal or noise?Authorship 9935741028654365Saha P, Regan MM, Pagani O, Francis PA, Walley BA, Ribi K, Bernhard J, Luo W, Gómez HL, Burstein HJ, Parmar V, Torres R, Stewart J, Bellet M, Perelló A, Dane F, Moreira A, Vorobiof D, Nottage M, Price KN, Coates AS, Goldhirsch A, Gelber RD, Colleoni M, Fleming GFJournal of clinical oncology : official journal of the American Society of Clinical OncologyTreatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials. J Clin Oncol. 2017 Sep 20; 35(27):3113-3122.J Clin Oncol2017-06-27T00:00:002017Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials.19562852Burstein HJHarvard health letterBy the way, doctor. I've been having PET-CT scans to look for any growth or spread of previously removed tumors. Are they as reliable in detecting breast cancer as a regular mammogram? Harv Health Lett. 2009 May; 34(7):2.Harv Health Lett2009-05-01T00:00:002009By the way, doctor. I've been having PET-CT scans to look for any growth or spread of previously removed tumors. Are they as reliable in detecting breast cancer as a regular mammogram?20971842Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Ljung BM, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Smith ML, Somlo G, Topham NS, Ward JH, Winer EP, Wolff ACJournal of the National Comprehensive Cancer Network : JNCCNBreast cancer: noninvasive and special situations. J Natl Compr Canc Netw. 2010 Oct; 8(10):1182-207.J Natl Compr Canc Netw2010-10-01T00:00:002010Breast cancer: noninvasive and special situations.21376386Lin NU, Burstein HJLancet (London, England)EMBRACE, eribulin, and new realities of advanced breast cancer. Lancet. 2011 Mar 12; 377(9769):878-80.Lancet2011-03-02T00:00:002011EMBRACE, eribulin, and new realities of advanced breast cancer.18581232Bafford AC, Burstein HJ, Barkley CR, Smith BL, Lipsitz S, Iglehart JD, Winer EP, Golshan MBreast cancer research and treatmentBreast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival. Breast Cancer Res Treat. 2009 May; 115(1):7-12.Breast Cancer Res Treat2008-06-26T00:00:002008Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival.18926092Figlin RA, Brown E, Armstrong AJ, Akerley W, Benson AB, Burstein HJ, Ettinger DS, Febbo PG, Fury MG, Hudes GR, Kies MS, Kwak EL, Morgan RJ, Mortimer J, Reckamp K, Venook AP, Worden F, Yen YJournal of the National Comprehensive Cancer Network : JNCCNNCCN Task Force Report: mTOR inhibition in solid tumors. J Natl Compr Canc Netw. 2008 Sep; 6 Suppl 5:S1-20; quiz S21-2.J Natl Compr Canc Netw2008-09-01T00:00:002008NCCN Task Force Report: mTOR inhibition in solid tumors.19755044Burstein HJJournal of the National Comprehensive Cancer Network : JNCCNColon cancer: the new breast cancer. J Natl Compr Canc Netw. 2009 Sep; 7(8):773.J Natl Compr Canc Netw2009-09-01T00:00:002009Colon cancer: the new breast cancer.19884535Burstein HJ, Winer EPJournal of clinical oncology : official journal of the American Society of Clinical OncologyRefining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy. J Clin Oncol. 2009 Dec 01; 27(34):5671-3.J Clin Oncol2009-11-02T00:00:002009Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy.21197188Burstein HJ, Griggs JJ, Prestrud AA, Temin SJournal of oncology practiceAmerican society of clinical oncology clinical practice guideline update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Oncol Pract. 2010 Sep; 6(5):243-6.J Oncol Pract2010-08-06T00:00:002010American society of clinical oncology clinical practice guideline update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.21550965Burstein HJJournal of the National Comprehensive Cancer Network : JNCCNTexting the doctor. J Natl Compr Canc Netw. 2011 May; 9(5):459.J Natl Compr Canc Netw2011-05-01T00:00:002011Texting the doctor.23001754Mayer EL, Isakoff SJ, Klement G, Downing SR, Chen WY, Hannagan K, Gelman R, Winer EP, Burstein HJBreast cancer research and treatmentCombination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics. Breast Cancer Res Treat. 2012 Nov; 136(1):169-78.Breast Cancer Res Treat2012-09-23T00:00:002012Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics.21310842Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Sachdev J, Smith ML, Somlo G, Ward JH, Wolff AC, Zellars RJournal of the National Comprehensive Cancer Network : JNCCNInvasive breast cancer. J Natl Compr Canc Netw. 2011 Feb; 9(2):136-222.J Natl Compr Canc Netw2011-02-01T00:00:002011Invasive breast cancer.21324674Shapiro CL, Halabi S, Hars V, Archer L, Weckstein D, Kirshner J, Sikov W, Winer E, Burstein HJ, Hudis C, Isaacs C, Schilsky R, Paskett EEuropean journal of cancer (Oxford, England : 1990)Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. Eur J Cancer. 2011 Mar; 47(5):683-9.Eur J Cancer2011-02-14T00:00:002011Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809.21715566Munzone E, Curigliano G, Burstein HJ, Winer EP, Goldhirsch AAnnals of oncology : official journal of the European Society for Medical OncologyCMF revisited in the 21st century. Ann Oncol. 2012 Feb; 23(2):305-11.Ann Oncol2011-06-29T00:00:002011CMF revisited in the 21st century.Authorship 1004526228838210Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B, André F, Baselga J, Bergh J, Bonnefoi H, Brucker SY, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Hussein K, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu BAnnals of oncology : official journal of the European Society for Medical OncologyDe-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2017 08 01; 28(8):1700-1712.Ann Oncol2017-08-01T00:00:002017De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.19439741Muss HB, Berry DA, Cirrincione CT, Theodoulou M, Mauer AM, Kornblith AB, Partridge AH, Dressler LG, Cohen HJ, Becker HP, Kartcheske PA, Wheeler JD, Perez EA, Wolff AC, Gralow JR, Burstein HJ, Mahmood AA, Magrinat G, Magrinat G, Parker BA, Hart RD, Grenier D, Norton L, Hudis CA, Winer EPThe New England journal of medicineAdjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med. 2009 May 14; 360(20):2055-65.N Engl J Med2009-05-14T00:00:002009Adjuvant chemotherapy in older women with early-stage breast cancer.20728696Curigliano G, Mayer EL, Burstein HJ, Winer EP, Goldhirsch AProgress in cardiovascular diseasesCardiac toxicity from systemic cancer therapy: a comprehensive review. Prog Cardiovasc Dis. 2010 Sep-Oct; 53(2):94-104.Prog Cardiovasc Dis2010-09-01T00:00:002010Cardiac toxicity from systemic cancer therapy: a comprehensive review.12506169Burstein HJ, Harris LN, Gelman R, Lester SC, Nunes RA, Kaelin CM, Parker LM, Ellisen LW, Kuter I, Gadd MA, Christian RL, Kennedy PR, Borges VF, Bunnell CA, Younger J, Smith BL, Winer EPJournal of clinical oncology : official journal of the American Society of Clinical OncologyPreoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol. 2003 Jan 01; 21(1):46-53.J Clin Oncol2003-01-01T00:00:002003Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study.17761968Burstein HJ, Winer EPJournal of clinical oncology : official journal of the American Society of Clinical OncologyAromatase inhibitors and arthralgias: a new frontier in symptom management for breast cancer survivors. J Clin Oncol. 2007 Sep 01; 25(25):3797-9.J Clin Oncol2007-09-01T00:00:002007Aromatase inhibitors and arthralgias: a new frontier in symptom management for breast cancer survivors.19078994Cirelli JA, Park CH, MacKool K, Taba M, Lustig KH, Burstein H, Giannobile WVGene therapyAAV2/1-TNFR:Fc gene delivery prevents periodontal disease progression. Gene Ther. 2009 Mar; 16(3):426-36.Gene Ther2008-12-11T00:00:002008AAV2/1-TNFR:Fc gene delivery prevents periodontal disease progression.21917620Burstein HJJournal of the National Comprehensive Cancer Network : JNCCNHave we been down this road before? J Natl Compr Canc Netw. 2011 Sep 01; 9(9):953.J Natl Compr Canc Netw2011-09-01T00:00:002011Have we been down this road before?22017599Barkley C, Burstein H, Smith B, Bellon J, Wong J, Gadd M, Taghian A, Winer E, Iglehart JD, Harris J, Golshan MThe breast journalCan axillary node dissection be omitted in a subset of patients with low local and regional failure rates? Breast J. 2012 Jan-Feb; 18(1):23-7.Breast J2011-10-21T00:00:002011Can axillary node dissection be omitted in a subset of patients with low local and regional failure rates?22679112Burstein HJJournal of the National Comprehensive Cancer Network : JNCCNThe top five in oncology: where do we go from here? J Natl Compr Canc Netw. 2012 Jun 01; 10(6):681-2.J Natl Compr Canc Netw2012-06-01T00:00:002012The top five in oncology: where do we go from here?22759093Schwartz GF, Bartelink H, Burstein HJ, Cady B, Cataliotti L, Fentiman IS, Holland R, Hughes KS, Masood S, McCormick B, Palazzo JA, Pressman PI, Reis-Filho J, Pusztai L, Rutgers EJ, Seidman AD, Solin LJ, Sparano JAThe breast journalAdjuvant therapy in stage I carcinoma of the breast: the influence of multigene analyses and molecular phenotyping. Breast J. 2012 Jul-Aug; 18(4):303-11.Breast J2012-07-01T00:00:002012Adjuvant therapy in stage I carcinoma of the breast: the influence of multigene analyses and molecular phenotyping.8123797Abbas AK, Burstein HJ, Bogen SASeminars in immunologyDeterminants of helper T cell-dependent antibody production. Semin Immunol. 1993 Dec; 5(6):441-7.Semin Immunol1993-12-01T00:00:001993Determinants of helper T cell-dependent antibody production.8426114Burstein HJ, Abbas AKThe Journal of experimental medicineIn vivo role of interleukin 4 in T cell tolerance induced by aqueous protein antigen. J Exp Med. 1993 Feb 01; 177(2):457-63.J Exp Med1993-02-01T00:00:001993In vivo role of interleukin 4 in T cell tolerance induced by aqueous protein antigen.12732612Winer EP, Hudis C, Burstein HJ, Bryant J, Chlebowski RT, Ingle JN, Edge SB, Mamounas EP, Gelber R, Gralow J, Goldstein LJ, Pritchard KI, Braun S, Cobleigh MA, Langer AS, Perotti J, Powles TJ, Whelan TJ, Browman GPJournal of clinical oncology : official journal of the American Society of Clinical OncologyAmerican Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting. J Clin Oncol. 2003 Jul 01; 21(13):2597-9.J Clin Oncol2003-05-05T00:00:002003American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting.12885806Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, Friedlander RJ, Gargiulo J, Strenger R, Vogel CL, Ryan PD, Ellis MJ, Nunes RA, Bunnell CA, Campos SM, Hallor M, Gelman R, Winer EPJournal of clinical oncology : official journal of the American Society of Clinical OncologyTrastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol. 2003 Aug 01; 21(15):2889-95.J Clin Oncol2003-08-01T00:00:002003Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.17114668Tolaney SM, Partridge AH, Sheib RG, Burstein HJ, Winer EPJournal of clinical oncology : official journal of the American Society of Clinical OncologyPneumocystis carinii pneumonia during dose-dense chemotherapy for breast cancer. J Clin Oncol. 2006 Nov 20; 24(33):5330-1.J Clin Oncol2006-11-20T00:00:002006Pneumocystis carinii pneumonia during dose-dense chemotherapy for breast cancer.15070793Burstein HJ, Polyak K, Wong JS, Lester SC, Kaelin CMThe New England journal of medicineDuctal carcinoma in situ of the breast. N Engl J Med. 2004 Apr 01; 350(14):1430-41.N Engl J Med2004-04-01T00:00:002004Ductal carcinoma in situ of the breast.Authorship 1019334329045519Dubsky P, Curigliano G, Burstein HJ, Winer EP, Gnant M, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B, André F, Baselga J, Bergh J, Bonnefoi H, Brucker SY, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Khaled H, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu BAnnals of oncology : official journal of the European Society for Medical OncologyReply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al. Ann Oncol. 2018 01 01; 29(1):281-282.Ann Oncol2018-01-01T00:00:002018Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al.21233239Burstein HJJournal of the National Comprehensive Cancer Network : JNCCNBeaten at the Alamo by the Europeans. J Natl Compr Canc Netw. 2011 Jan; 9(1):1.J Natl Compr Canc Netw2011-01-01T00:00:002011Beaten at the Alamo by the Europeans.18421051Lin NU, Carey LA, Liu MC, Younger J, Come SE, Ewend M, Harris GJ, Bullitt E, Van den Abbeele AD, Henson JW, Li X, Gelman R, Burstein HJ, Kasparian E, Kirsch DG, Crawford A, Hochberg F, Winer EPJournal of clinical oncology : official journal of the American Society of Clinical OncologyPhase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2008 Apr 20; 26(12):1993-9.J Clin Oncol2008-04-20T00:00:002008Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.18317961Burstein HJCancer investigationPreoperative therapy as a model for translational research in breast cancer. Cancer Invest. 2008 Apr-May; 26(3):217-21.Cancer Invest2008-04-01T00:00:002008Preoperative therapy as a model for translational research in breast cancer.16236735Burstein HJThe New England journal of medicineThe distinctive nature of HER2-positive breast cancers. N Engl J Med. 2005 Oct 20; 353(16):1652-4.N Engl J Med2005-10-20T00:00:002005The distinctive nature of HER2-positive breast cancers.16800976Burstein HJ, Mayer E, Patridge AH, O'Kane H, Litsas G, Come SE, Hudis CA, Goldstein DF, Muss HB, Winter EP, Garber JEClinical breast cancerInadvertent use of aromatase inhibitors in patients with breast cancer with residual ovarian function: cases and lessons. Clin Breast Cancer. 2006 Jun; 7(2):158-61.Clin Breast Cancer2006-06-01T00:00:002006Inadvertent use of aromatase inhibitors in patients with breast cancer with residual ovarian function: cases and lessons.10715290Burstein HJ, Manola J, Younger J, Parker LM, Bunnell CA, Scheib R, Matulonis UA, Garber JE, Clarke KD, Shulman LN, Winer EPJournal of clinical oncology : official journal of the American Society of Clinical OncologyDocetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol. 2000 Mar; 18(6):1212-9.J Clin Oncol2000-03-01T00:00:002000Docetaxel administered on a weekly basis for metastatic breast cancer.18234758Burstein HJ, Schwartz RSThe New England journal of medicineMolecular origins of cancer. N Engl J Med. 2008 Jan 31; 358(5):527.N Engl J Med2008-01-31T00:00:002008Molecular origins of cancer.18347007Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, Baum CM, Miller KDJournal of clinical oncology : official journal of the American Society of Clinical OncologyPhase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2008 Apr 10; 26(11):1810-6.J Clin Oncol2008-03-17T00:00:002008Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.12057079Spigel DR, Burstein HJCurrent treatment options in oncologyHER2 overexpressing metastatic breast cancer. Curr Treat Options Oncol. 2002 Apr; 3(2):163-74.Curr Treat Options Oncol2002-04-01T00:00:002002HER2 overexpressing metastatic breast cancer.Authorship 10286272229158011Colleoni M, Luo W, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, Neven P, Hitre E, Graas MP, Simoncini E, Kamby C, Thompson A, Loibl S, Gavilá J, Kuroi K, Marth C, Müller B, O'Reilly S, Di Lauro V, Gombos A, Ruhstaller T, Burstein H, Ribi K, Bernhard J, Viale G, Maibach R, Rabaglio-Poretti M, Gelber RD, Coates AS, Di Leo A, Regan MM, Goldhirsch AThe Lancet. OncologyExtended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018 01; 19(1):127-138.Lancet Oncol2017-11-17T00:00:002017Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.20870630Burstein HJJournal of the National Comprehensive Cancer Network : JNCCNAvastin, ODAC, and the FDA: are we drafting the right players? J Natl Compr Canc Netw. 2010 Aug; 8(8):833-4.J Natl Compr Canc Netw2010-08-01T00:00:002010Avastin, ODAC, and the FDA: are we drafting the right players?17345004Lin NU, Parker LM, Come SE, Burstein HJ, Haldoupis M, Ryabin N, Gelman R, Winer EP, Shulman LNInvestigational new drugsPhase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions. Invest New Drugs. 2007 Aug; 25(4):369-75.Invest New Drugs2007-03-08T00:00:002007Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions.17368903Burstein HJBreast (Edinburgh, Scotland)Aromatase inhibitor-associated arthralgia syndrome. Breast. 2007 Jun; 16(3):223-34.Breast2007-03-21T00:00:002007Aromatase inhibitor-associated arthralgia syndrome.17439758Carlson RW, Anderson BO, Burstein HJ, Carter WB, Edge SB, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Jahanzeb M, Ljung BM, Kiel K, Marks LB, McCormick B, Nabell LM, Pierce LJ, Reed EC, Silver SM, Smith ML, Somlo G, Theriault RL, Ward JH, Winer EP, Wolff ACJournal of the National Comprehensive Cancer Network : JNCCNInvasive breast cancer. J Natl Compr Canc Netw. 2007 Mar; 5(3):246-312.J Natl Compr Canc Netw2007-03-01T00:00:002007Invasive breast cancer.18757263Tolaney SM, Najita J, Winer EP, Burstein HJClinical breast cancerLymphopenia associated with adjuvant anthracycline/ taxane regimens. Clin Breast Cancer. 2008 Aug; 8(4):352-6.Clin Breast Cancer2008-08-01T00:00:002008Lymphopenia associated with adjuvant anthracycline/ taxane regimens.22614986Burstein HJ, Piccart-Gebhart MJ, Perez EA, Hortobagyi GN, Wolmark N, Albain KS, Norton L, Winer EP, Hudis CAJournal of clinical oncology : official journal of the American Society of Clinical OncologyChoosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines? J Clin Oncol. 2012 Jun 20; 30(18):2179-82.J Clin Oncol2012-05-21T00:00:002012Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines?23307974Burstein HJJournal of the National Comprehensive Cancer Network : JNCCNCaring for breast cancer survivors. J Natl Compr Canc Netw. 2013 Jan 01; 11(1):1-2.J Natl Compr Canc Netw2013-01-01T00:00:002013Caring for breast cancer survivors.17317830Harris LN, You F, Schnitt SJ, Witkiewicz A, Lu X, Sgroi D, Ryan PD, Come SE, Burstein HJ, Lesnikoski BA, Kamma M, Friedman PN, Gelman R, Iglehart JD, Winer EPClinical cancer research : an official journal of the American Association for Cancer ResearchPredictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res. 2007 Feb 15; 13(4):1198-207.Clin Cancer Res2007-02-15T00:00:002007Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer.19179558Blackwell KL, Pegram MD, Tan-Chiu E, Schwartzberg LS, Arbushites MC, Maltzman JD, Forster JK, Rubin SD, Stein SH, Burstein HJAnnals of oncology : official journal of the European Society for Medical OncologySingle-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. Ann Oncol. 2009 Jun; 20(6):1026-31.Ann Oncol2009-01-29T00:00:002009Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens.19322949Gold JM, Burstein HJOncology (Williston Park, N.Y.)Improving tolerance of AIs: predicting risk and uncovering mechanisms of musculoskeletal toxicity. Oncology (Williston Park). 2008 Nov 15; 22(12):1416, 1424.Oncology (Williston Park)2008-11-15T00:00:002008Improving tolerance of AIs: predicting risk and uncovering mechanisms of musculoskeletal toxicity.450 Brookline AveDana Farber Cancer InstituteYawkey 12th floor450 Brookline AveBoston02215MA19675333Burstein HJ, Souter I, D'Alessandro HA, Sgroi DCThe New England journal of medicineCase records of the Massachusetts General Hospital. Case 25-2009. A 36-year-old woman with hormone-receptor-positive breast cancer. N Engl J Med. 2009 Aug 13; 361(7):699-707.N Engl J Med2009-08-13T00:00:002009Case records of the Massachusetts General Hospital. Case 25-2009. A 36-year-old woman with hormone-receptor-positive breast cancer.21715720Burstein HJJournal of the National Comprehensive Cancer Network : JNCCNThe fifth "C" is cost: highlights from ASCO 2011. J Natl Compr Canc Netw. 2011 Jul 01; 9(7):691.J Natl Compr Canc Netw2011-07-01T00:00:002011The fifth "C" is cost: highlights from ASCO 2011.22157551Burstein HJJournal of the National Comprehensive Cancer Network : JNCCNAvastin for breast cancer, 2005-2011: requiescat in pacem? J Natl Compr Canc Netw. 2011 Dec; 9(12):1321-3.J Natl Compr Canc Netw2011-12-01T00:00:002011Avastin for breast cancer, 2005-2011: requiescat in pacem?22393189Burstein HJJournal of the National Comprehensive Cancer Network : JNCCNPre-judging data: benchmarking clinical significance before study results are known. J Natl Compr Canc Netw. 2012 Mar; 10(3):289-90.J Natl Compr Canc Netw2012-03-01T00:00:002012Pre-judging data: benchmarking clinical significance before study results are known.19200416Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Jahanzeb M, Kiel K, Ljung BM, Marcom PK, Mayer IA, McCormick B, Nabell LM, Pierce LJ, Reed EC, Smith ML, Somlo G, Theriault RL, Topham NS, Ward JH, Winer EP, Wolff ACJournal of the National Comprehensive Cancer Network : JNCCNBreast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2009 Feb; 7(2):122-92.J Natl Compr Canc Netw2009-02-01T00:00:002009Breast cancer. Clinical practice guidelines in oncology.19294501Mayer EL, Partridge AH, Harris LN, Gelman RS, Schumer ST, Burstein HJ, Winer EPBreast cancer research and treatmentTolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer. Breast Cancer Res Treat. 2009 Oct; 117(3):615-23.Breast Cancer Res Treat2009-03-18T00:00:002009Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer.20625130Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Malin J, Mamounas EP, Rowden D, Solky AJ, Sowers MR, Stearns V, Winer EP, Somerfield MR, Griggs JJJournal of clinical oncology : official journal of the American Society of Clinical OncologyAmerican Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol. 2010 Aug 10; 28(23):3784-96.J Clin Oncol2010-07-12T00:00:002010American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.21464142Burstein HJJournal of the National Comprehensive Cancer Network : JNCCNMind the gap. J Natl Compr Canc Netw. 2011 Apr; 9(4):343.J Natl Compr Canc Netw2011-04-01T00:00:002011Mind the gap.22211134Ajani JA, Mangu PB, Burstein HJJournal of oncology practicePeek before you treat? Is it a fantasy or reality? J Oncol Pract. 2011 Sep; 7(5):338-9.J Oncol Pract2011-09-01T00:00:002011Peek before you treat? Is it a fantasy or reality?22271478Burstein HJ, Griggs JJJournal of clinical oncology : official journal of the American Society of Clinical OncologyDeep time: the long and the short of adjuvant endocrine therapy for breast cancer. J Clin Oncol. 2012 Mar 01; 30(7):684-6.J Clin Oncol2012-01-23T00:00:002012Deep time: the long and the short of adjuvant endocrine therapy for breast cancer.22392584Katz ML, Archer LE, Peppercorn JM, Kereakoglow S, Collyar DE, Burstein HJ, Schilsky RL, Partridge AHCancerPatient advocates' role in clinical trials: perspectives from Cancer and Leukemia Group B investigators and advocates. Cancer. 2012 Oct 01; 118(19):4801-5.Cancer2012-03-05T00:00:002012Patient advocates' role in clinical trials: perspectives from Cancer and Leukemia Group B investigators and advocates.19878636Burstein HJJournal of the National Comprehensive Cancer Network : JNCCNWhat is a patient navigator, and should we have them in major cancer centers? J Natl Compr Canc Netw. 2009 Oct; 7(9):905.J Natl Compr Canc Netw2009-10-01T00:00:002009What is a patient navigator, and should we have them in major cancer centers?20124187Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, Ellis C, Casey M, Vukelja S, Bischoff J, Baselga J, O'Shaughnessy JJournal of clinical oncology : official journal of the American Society of Clinical OncologyRandomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010 Mar 01; 28(7):1124-30.J Clin Oncol2010-02-01T00:00:002010Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.21531783Olson EM, Lin NU, DiPiro PJ, Najita JS, Krop IE, Winer EP, Burstein HJAnnals of oncology : official journal of the European Society for Medical OncologyResponses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer. Ann Oncol. 2012 Jan; 23(1):93-97.Ann Oncol2011-04-29T00:00:002011Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer.22056653Burstein HJJournal of the National Comprehensive Cancer Network : JNCCNThe continuity of care checklist: a critical frontier in patient safety. J Natl Compr Canc Netw. 2011 Nov; 9(11):1217-8.J Natl Compr Canc Netw2011-11-01T00:00:002011The continuity of care checklist: a critical frontier in patient safety.22223863Burstein HJJournal of the National Comprehensive Cancer Network : JNCCNJNCCN reaches 10. J Natl Compr Canc Netw. 2012 Jan; 10(1):3.J Natl Compr Canc Netw2012-01-01T00:00:002012JNCCN reaches 10.22927527Lyman GH, Burstein HJ, Buzdar AU, D'Agostino R, Ellis PAJournal of clinical oncology : official journal of the American Society of Clinical OncologyMaking genuine progress against metastatic breast cancer. J Clin Oncol. 2012 Oct 01; 30(28):3448-51.J Clin Oncol2012-08-27T00:00:002012Making genuine progress against metastatic breast cancer.Authorship 10442602229380678Heymach J, Krilov L, Alberg A, Baxter N, Chang SM, Corcoran RB, Dale W, DeMichele A, Magid Diefenbach CS, Dreicer R, Epstein AS, Gillison ML, Graham DL, Jones J, Ko AH, Lopez AM, Maki RG, Rodriguez-Galindo C, Schilsky RL, Sznol M, Westin SN, Burstein HJournal of clinical oncology : official journal of the American Society of Clinical OncologyClinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2018 04 01; 36(10):1020-1044.J Clin Oncol2018-01-30T00:00:002018Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.12149307Chlebowski RT, Col N, Winer EP, Collyar DE, Cummings SR, Vogel VG, Burstein HJ, Eisen A, Lipkus I, Pfister DGJournal of clinical oncology : official journal of the American Society of Clinical OncologyAmerican Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol. 2002 Aug 01; 20(15):3328-43.J Clin Oncol2002-08-01T00:00:002002American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition.14715107Spigel DR, Burstein HJClinical breast cancerTrastuzumab regimens for HER2-overexpressing metastatic breast cancer. Clin Breast Cancer. 2003 Dec; 4(5):329-37; discussion 338-9.Clin Breast Cancer2003-12-01T00:00:002003Trastuzumab regimens for HER2-overexpressing metastatic breast cancer.16969707Burstein HJ, Overmoyer B, Gelman R, Silverman P, Savoie J, Clarke K, Dumadag L, Younger J, Ivy P, Winer EPInvestigational new drugsRebeccamycin analog for refractory breast cancer: a randomized phase II trial of dosing schedules. Invest New Drugs. 2007 Apr; 25(2):161-4.Invest New Drugs2006-09-13T00:00:002006Rebeccamycin analog for refractory breast cancer: a randomized phase II trial of dosing schedules.12644548Partridge AH, Burstein HJ, Gelman RS, Marcom PK, Winer EPJournal of the National Cancer InstituteDo patients participating in clinical trials want to know study results? J Natl Cancer Inst. 2003 Mar 19; 95(6):491-2.J Natl Cancer Inst2003-03-19T00:00:002003Do patients participating in clinical trials want to know study results?12784331Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, Bunnell C, Rue M, Gelman R, Winer ECancerCentral nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer. 2003 Jun 15; 97(12):2972-7.Cancer2003-06-15T00:00:002003Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.